Comprehensive University Study Notes in Immunology

Academic Curriculum and Assessment Framework in Immunology

• Course Administration & Credit Weight:

  • Course Codes: ARMP.02.007 (5 EAP; 1 semester duration comprising 22 lecture hours and 34 seminar hours) and ARMP.02.004 (6 EAP; Research Foundations in Immunology / Immunoloogia alase uurimistöö alused I).

  • Instructional Faculty: Kai Kisand, Koit Reimand, Aili Tagoma, Alar Aints, Ivo Laidmäe, Brita Laht, Liis Haljamägi, Tuuliki Pomerants, Krista Ress, Maris Tulk, Julia Maslovskaja, and Maire Mandel.

  • Primary Textbooks:

  • Basic Immunology: Functions and Disorders of the Immune System (Abul K. Abbas, Andrew H. Lichtman, and Shiv Pillai; 3rd, 4th, 5th, and 7th Editions, Elsevier/Saunders).

  • Janeway's Immunobiology (Kenneth Murphy, Paul Travers, Mark Walport; Garland Science).

  • Crash Course: Immunology (Robert Novick, James Craster, 2006).

  • How the Immune System Works (Lauren Sompayrac).

  • Immune: A Journey into the Mysterious System That Keeps You Alive (Philipp Dettmer / Kurzgesagt).

• Mandatory Course Requirements:

  • Participation in all interactive seminars is strictly mandatory. An absence mandates presenting an individual oral seminar presentation and discussion during an ad hoc scheduled slot (typically Friday afternoons).

  • Post-seminar Moodle quizzes covering central seminar concepts must be completed promptly; failure to submit without reminders results in a formal warning ("yellow card").

  • The final seminar consists of student group presentations (10–15 minutes per group of 3–4 students) paired with a structured journal club analyzing a published peer-reviewed research study.

• Lecture Tests and Grading System:

  • First Lecture Test (October 15, 2026): Non-differentiated assessment covering general basic immunology and immunological laboratory methods (Abbas, Chapters 1–8). Conducted in the lecture auditorium via personal laptops. A minimum passing threshold of $75\%$ of total points is required. Students are permitted a maximum of 3 attempts. Failing this test results in a permanent 10 percentage-point reduction in the student's final examination score.

  • Second Lecture Test (December 3, 2026): Non-differentiated assessment covering clinical and medical immunology (hypersensitivity, autoimmunity, infectious disease immunology, immunodeficiencies, transplantation and tumor immunology, biologics, and vaccines; Abbas, Chapters 9–12). Conducted in the auditorium on personal laptops with a $75\%$ pass threshold; does not directly alter the final examination score.

  • Final Examination Structure: Held in the auditorium consisting of a comprehensive test of up to 100 questions of varied design, evaluated on a differentiated scale:

  • Grade A: $91\% - 100\%$

  • Grade B: $81\% - <91\%$

  • Grade C: $71\% - <81\%$

  • Grade D: $61\% - <71\%$

  • Grade E: $51\% - <61\%$

  • Grade F: $<51\%$

• Scientific Literature Exploration in Type 1 Diabetes (T1D):

  • Investigation of transcription factor 7-like 2 (TCF7L2) single-nucleotide polymorphism (SNP rs7903146) in 190 newly diagnosed T1D pediatric patients (median age 12.7 years, range 2.0–72.5) versus 246 population controls (median age 23.8 years, range 1.4–81.5).

  • While overall allele distribution did not differ between cohorts, T1D patients carrying the C allele exhibited a markedly higher risk of severe insulinopenia ($\text{C-peptide} < 0.5\,\text{nmol/L}$, $\text{OR} = 5.65$, $95\%\,\text{CI}: 1.14 - 27.92$) and zinc transporter 8 autoantibody (ZnT8A) seropositivity ($\text{OR} = 5.22$, $95\%\,\text{CI}: 1.34 - 20.24$).

  • Patients lacking the T allele showed significantly elevated titers of islet antigen-2 autoantibodies (IA-2A; $\text{OR} = 3.51$, $95\%\,\text{CI}: 1.49 - 8.27$) and ZnT8A ($\text{OR} = 2.39$, $95\%\,\text{CI}: 1.14 - 4.99$).

Evolutionary Milestones and Defensive Architecture

• Historical Foundations of Modern Immunology:

  • Robert Koch: Identified causative bacterial agents of tuberculosis (Mycobacterium tuberculosis), cholera (Vibrio cholerae), and anthrax (Bacillus anthracis); pioneered bacterial culture techniques and tuberculin isolation.

  • Emil von Behring & Kitasato Shibasaburō: Discovered humoral antitoxins against diphtheria (Corynebacterium diphtheriae) and tetanus (Clostridium tetani), establishing serum therapy and passive immunization.

  • Paul Ehrlich: Formulated the side-chain theory of antibody-antigen interaction, standardized antiserum potency, and conceptualized the "magic bullet" targeting mechanism.

  • Alexandre Yersin: Identified Yersinia pestis as the etiological agent of bubonic plague.

  • Rudolf Virchow: Formulated cellular pathology (omnis cellula e cellula), describing diseases as aberrations in normal cellular physiology.

  • Ernst von Bergmann: Pioneer of surgical asepsis, carbolized dressings, and steam-heat sterilization who studied at Tartu University.

• Three Lines of Defense:

  • 1. Intrinsic Resistance & Physiological Barriers:

  • Mechanical: Tightly knit stratified squamous epithelial layers of skin and simple columnar epithelial barriers in mucosal tracts sealed by occluding zonulae (tight junctions); mucociliary escalator sweeps trapped particulate debris out of the respiratory tree.

  • Chemical: High acidity of gastric secretions ($\text{pH} \approx 1.5 - 3.5$), sebum fatty acids on cutaneous surfaces, and antimicrobial enzymes (e.g., lysozyme in lacrimal secretions and saliva cleaving $\beta(1\rightarrow 4)$ glycosidic bonds between N-acetylmuramic acid and N-acetylglucosamine in bacterial peptidoglycan).

  • Microbiological: Commensal microbiota occupying epithelial niches, monopolizing metabolic substrates, producing bacteriocins, and preventing colonization by pathogenic invaders through competitive exclusion and quorum-sensing interference.

  • 2. Innate Immunity: Non-specific, pattern-based recognition operational within minutes to hours; displays no antigen-specific memory and uses invariant germline-encoded receptors to coordinate local inflammation and phagocytic eradication.

  • 3. Adaptive Immunity: Highly customized, specific defensive system mediated by clonally expanded T and B lymphocytes; requires days to weeks for initial priming but generates long-lived immunological memory.

• Anatomical Organization of Lymphoid Tissues:

  • Primary (Generative) Lymphoid Organs:

  • Bone Marrow: Site of pluripotent hematopoietic stem cell (HSC) maintenance, lineage commitment, myelopoiesis, and complete B-cell lymphopoiesis.

  • Thymus: Bilobed mediastinal organ facilitating thymocyte education, T-cell receptor (TCR) gene rearrangements, positive selection (cortex), and negative selection (medulla); undergoes progressive age-related fatty involution.

  • Secondary (Peripheral) Lymphoid Organs:

  • Lymph Nodes: Encapsulated filters distributed along lymphatic channels that sample tissue-derived lymph fluid, concentrating dendritic cells, soluble antigens, and naive recirculating lymphocytes.

  • Spleen: Vascular filter specializing in systemic blood surveillance; periarteriolar lymphoid sheaths (PALS) house T cells, while adjacent follicles house B cells to combat blood-borne pathogens.

  • Mucosa-Associated Lymphoid Tissue (MALT): Unencapsulated or semi-encapsulated lymphoid aggregates lining mucosal portals of entry, including tonsils, adenoids, bronchial lymphoid aggregates (BALT), and intestinal Peyer's patches (GALT).

Hematopoiesis and the Innate Cellular Frontline

• Hematopoietic Lineage Differentiation:

  • Pluripotent $CD34^+$ hematopoietic stem cells divide and differentiate into two primary progenitor pathways:

  • Common Myeloid Progenitor (CMP): Generates megakaryocytes (producing platelets), erythroblasts (producing erythrocytes), mast cell precursors, myeloblasts (giving rise to basophils, eosinophils, and neutrophils), and monoblasts (giving rise to blood monocytes, which migrate into tissues to form macrophages and myeloid dendritic cells).

  • Common Lymphoid Progenitor (CLP): Gives rise to B-cell precursors, T-cell thymocyte precursors, natural killer (NK) cells, and helper-like innate lymphoid cells (ILCs).

• Distinguishing Properties of Peripheral Leukocytes:

• Neutrophils (Polymorphonuclear Leukocytes, PMNs):

  • Morphology & Size: $12 - 15\,\mu\text{m}$ in diameter, characterized by a multi-lobed nucleus (3–5 segments interconnected by fine chromatin threads) and neutral-staining granules.

  • Abundance & Kinetics: Constitute $50\% - 70\%$ of circulating leukocytes; rapid responders entering tissues within minutes to hours of acute injury; tissue lifespan is limited to $1 - 2\,\text{days}$, circulating blood lifespan is $\approx 5\,\text{days}$.

  • Antimicrobial Mechanisms: High-capacity phagocytosis, rapid respiratory burst via NADPH oxidase activation, degranulation (primary azurophilic granules containing myeloperoxidase, elastase, cathepsin G; secondary specific granules containing lactoferrin and lysozyme), and Neutrophil Extracellular Trap (NET) extrusion.

  • Absence in Normal States: Neutrophils do not reside in healthy resting tissues; extravasation occurs solely during acute inflammation, forming the cellular bulk of purulent exudate (pus).

• Monocytes and Macrophages:

  • Morphology & Size: Monocytes are large mononuclear cells ($10 - 15\,\mu\text{m}$) with an indented, kidney-shaped nucleus and agranular appearance under light microscopy.

  • Tissue-Resident Macrophage Ontogeny: Many tissue-resident populations arise from yolk sac or fetal liver progenitors during embryogenesis and self-renew locally throughout adult life (e.g., microglia in brain, Kupffer cells in liver, alveolar macrophages in lungs, osteoclasts in bone, sinusoidal macrophages in spleen, and dermal macrophages in skin). Inflammatory macrophages derive directly from adult bone-marrow $CD14^+$ monocytes extravasating into damaged sites.

  • Longevity & Kinetics: Tissue-resident macrophages survive for months to years; responses to activating stimuli are prolonged, slower than neutrophils, and heavily dependent on de novo transcription.

  • Key Effector Mechanisms: Prolonged clearance of microbial invaders, apoptotic cellular corpses (efferocytosis), foreign matter, and tissue debris; nitric oxide (NO) generation via inducible nitric oxide synthase (iNOS); antigen presentation on MHC Class II; secretion of pro-inflammatory cytokines ($TNF-\alpha$, $IL-1\beta$, $IL-6$, $IL-12$); and orchestration of tissue fibrosis and wound healing via collagen deposition and angiogenic factor synthesis ($VEGF$, $bFGF$).

• Eosinophils:

  • Morphology & Staining: $12 - 17\,\mu\text{m}$ in diameter, bilobed nucleus, packed with large cytoplasmic granules that stain intensely bright pink/red with acidic dyes (eosin).

  • Functional Scope: Primary defense against large extracellular multicellular helminthic parasites (e.g., Schistosoma, Ascaris, Trichinella); mediate tissue remodeling and late-phase allergic inflammation.

  • Granule Contents: Major basic protein (MBP), eosinophil cationic protein (ECP), eosinophil peroxidase (EPO), and eosinophil neurotoxin (EDN).

  • Distribution: Normal tissue residency in the gastrointestinal lamina propria; normally excluded from lung parenchyma, esophagus, and skin unless recruited by allergic or eosinophilic disease.

• Basophils:

  • Morphology & Staining: $10 - 16\,\mu\text{m}$ in diameter, lobed nucleus obscured by large, dark blue/purple granules that bind basic dyes (hematoxylin).

  • Abundance: Rarest circulating leukocyte, representing $<1\%$ of peripheral white blood cells; non-phagocytic.

  • Granule Contents: High concentrations of preformed histamine, proteoglycans (heparin, chondroitin sulfate), and protease enzymes; express high-affinity $Fc\epsilon RI$ to initiate immediate allergic reactions and defend against ectoparasites (e.g., ticks).

• Mast Cells:

  • Morphology & Location: Tissue-bound agranular/mononuclear-appearing sentinels located adjacent to mucosal surfaces, dermal blood vessels, and peripheral nerves; do not circulate as mature cells in the bloodstream.

  • Granule Mediators: Rich in histamine, heparin, neutral proteases (tryptase, chymase), and carboxypeptidase; rapidly activated via direct degranulation or antigen-mediated cross-linking of surface-bound IgE-$Fc\epsilon RI$ complexes.

• Dendritic Cells (DCs):

  • Classical (Conventional) DCs (cDCs): Professional antigen-presenting cells residing in peripheral tissues; cDC1 subsets excel at cross-presenting exogenous antigens on MHC Class I to prime naive $CD8^+$ cytotoxic T lymphocytes, whereas cDC2 subsets preferentially present via MHC Class II to prime naive $CD4^+$ helper T cells.

  • Plasmacytoid DCs (pDCs): Possess plasma cell-like morphology; circulate in blood and secondary lymphoid organs, expressing high basal levels of endosomal TLR7 and TLR9 to rapidly produce copious amounts of Type I interferons ($IFN-\alpha$, $IFN-\beta$) upon encountering viral nucleic acids.

  • Monocyte-Derived DCs (moDCs): Arise in situ from extravasated blood monocytes during periods of severe tissue inflammation.

  • Langerhans Cells: Specialized dendritic cells stationed within the epidermal stratum spinosum of the skin, containing tennis racket-shaped Birbeck granules.

Phagocytosis, the Oxidative Burst, and Inflammatory Cascades

• Biochemical Steps of Phagocytic Killing:

  • 1. Target Entrapment & Phagosome Formation: Receptor-mediated attachment (via scavenger receptors, Dectin-1, mannose receptors, or opsonin receptors such as $Fc\gamma R$ and complement receptors CR1/CR3/CR4) induces localized actin polymerization. Plasma membrane pseudopods envelop the foreign particle, sealing it into an intracellular endocytic vacuole called the phagosome.

  • 2. Phagolysosomal Fusion: The phagosome translocates along microtubules and fuses with acidic lysosomes to form the phagolysosome. Vacuolar-type $H^+\text{-ATPases}$ pump protons into the lumen, lowering internal $\text{pH}$ to $4.5 - 5.0$. However, acidification alone is bacteriostatic, accounting for only $\approx 2\%$ of direct pathogen eradication.

  • 3. The Respiratory (Oxidative) Burst:

  • Phagocytic stimulus triggers assembly of the multi-component enzyme complex NADPH oxidase (phagocyte oxidase) at the phagolysosomal membrane.

  • Cytosolic subunits ($p47^{phox}$, $p67^{phox}$, $p40^{phox}$, and Rac GTPase) translocate to join the membrane-bound heterodimer cytochrome $b_{558}$ (composed of $gp91^{phox}$ and $p22^{phox}$).

  • The active complex transfers electrons from cytosolic NADPH across the membrane to molecular oxygen ($O_2$), generating superoxide free radicals:       $\text{NADPH} + 2\,O_2 \xrightarrow{\text{NADPH Oxidase}} \text{NADP}^+ + H^+ + 2\,O_2^{\bullet-}$

  • Superoxide is rapidly converted by superoxide dismutase (SOD) into hydrogen peroxide ($H_2O_2$):       $2\,O_2^{\bullet-} + 2\,H^+ \xrightarrow{\text{SOD}} O_2 + H_2O_2$

  • In neutrophils, primary azurophilic granules deliver myeloperoxidase (MPO), which uses chloride ($Cl^-$) and hydrogen peroxide to synthesize highly toxic hypochlorous acid ($\text{HOCl}$, the active agent of household bleach):       $H_2O_2 + Cl^- \xrightarrow{\text{MPO}} \text{HOCl} + OH^-$

  • Inducible nitric oxide synthase (iNOS), particularly in macrophages, synthesizes nitric oxide ($\text{NO}^{\bullet}$) from L-arginine; $\text{NO}^{\bullet}$ reacts with superoxide ($O_2^{\bullet-}$) to form peroxynitrite ($\text{ONOO}^-$), a potent reactive nitrogen species (RNS) that induces lipid peroxidation, protein nitration, and DNA strand breaks.

  • Pathology of Chronic Granulomatous Disease (CGD):

  • Inherited immunodeficiency caused by loss-of-function mutations in genes encoding NADPH oxidase subunits (most commonly X-linked mutations in $CYBB$ encoding $gp91^{phox}$, or autosomal recessive mutations in $CYBA$, $NCF1$, $NCF2$).

  • Phagocytes successfully ingest microbes but cannot produce superoxide radicals or reactive oxygen intermediates, disabling intracellular killing.

  • Patients suffer severe, recurrent deep bacterial and fungal infections caused by catalase-positive organisms (e.g., Staphylococcus aureus, Aspergillus species, Serratia marcescens, Burkholderia cepacia, Nocardia), which degrade endogenous microbial $H_2O_2$.

  • The persistent failure to clear ingested antigens leads to chronic cell-mediated immune responses, causing extensive granuloma formation throughout the gastrointestinal, urogenital, and reticuloendothelial systems.

• Acute Inflammatory Sequence and the Vascular Cascade:

• 1. Five Cardinal Local Signs of Inflammation:

  • Rubor (Redness): Driven by arteriolar vasodilation expanding local blood volume.

  • Calor (Heat): Caused by increased regional vascular perfusion.

  • Tumor (Swelling): Caused by increased microvascular permeability and plasma protein extravasation (exudate formation).

  • Dolor (Pain): Triggered by mechanical tissue distortion and direct chemical sensitization of sensory nerve endings by bradykinin, prostaglandins ($PGE_2$), and histamine.

  • Functio Laesa (Loss of Function): Functional disruption caused by tissue destruction, edema, and reflex pain inhibition.

• 2. Leukocyte Extravasation Multistep Cascade:

  • Margination & Rolling: Vasodilation causes local blood flow to decelerate (stasis). Circulating leukocytes diverge from the central axial stream toward the endothelial margins. Endothelial cells, stimulated by $TNF-\alpha$ and $IL-1$, express selectins (P-selectin mobilized from Weibel-Palade bodies; E-selectin synthesized de novo). Selectins bind sialylated carbohydrate ligands (e.g., sialyl Lewis X) on leukocyte microvilli with low affinity, causing cells to tumble along the vessel wall.

  • Firm Adhesion: Endothelial cells display chemokines (e.g., CXCL8/IL-8) that bind leukocyte G-protein-coupled receptors, triggering an inside-out conformational shift that converts low-affinity leukocyte integrins (LFA-1, Mac-1, VLA-4) to a high-affinity extended state. These high-affinity integrins lock onto endothelial immunoglobulin superfamily molecules (ICAM-1, VCAM-1), arresting leukocyte rolling.

  • Diapedesis (Transmigration): Leukocytes crawl through widened inter-endothelial junctions mediated by homophilic PECAM-1 (CD31) interactions, cross the basal lamina via local matrix metalloproteinase digestion, and enter the extravascular space.

  • Chemotaxis: Extravasated leukocytes migrate along concentration gradients of exogenous chemoattractants (bacterial N-formyl peptides) and endogenous chemoattractants (C5a, leukotriene $B_4$, and CXCL8) directly to the site of tissue trauma.

Pattern Recognition Receptors and the Inflammasome

• Pattern Recognition Receptors (PRRs):

  • Germline-encoded sensors that detect evolutionary conserved, essential microbial motifs known as Pathogen-Associated Molecular Patterns (PAMPs), or endogenous stress indicators termed Damage-Associated Molecular Patterns (DAMPs).

  • The Wasp Analogy: Just as high-contrast alternating yellow-and-black stripes instantly signal the danger of a wasp sting prior to formal entomological identification, PRRs rapidly identify invariant molecular motifs (such as repeating glycolipid or nucleic acid arrays) to launch defensive countermeasures before adaptive clonal identification occurs.

• Receptor Families, Localization, and Ligand Specificity:

- **Toll-Like Receptors (TLRs):** Type I transmembrane glycoproteins featuring an extracellular/luminal domain composed of leucine-rich repeats (LRRs) for ligand binding and an intracellular Toll/Interleukin-1 Receptor (TIR) domain for downstream signaling.
  - *Plasma Membrane TLRs:* 
    - **TLR4:** Recognizes lipopolysaccharide (LPS / endotoxin) from Gram-negative bacterial outer membranes in a complex with MD-2, CD14, and LPS-binding protein (LBP).
    - **TLR2/TLR1 Heterodimer:** Binds triacylated bacterial lipoproteins, mycobacterial lipoarabinomannan (LAM), and unconventional LPS.
    - **TLR2/TLR6 Heterodimer:** Binds diacylated mycoplasmal lipoproteins, peptidoglycan, and fungal zymosan.
    - **TLR5:** Binds flagellin monomers from bacterial flagella.
    - **TLR11:** Detects protozoan profilin.
  - *Endosomal TLRs (Intracellular Nucleic Acid Sensors):*
    - **TLR3:** Binds viral double-stranded RNA (dsRNA).
    - **TLR7 & TLR8:** Detect single-stranded viral RNA (ssRNA); pharmacologically stimulated by synthetic imidazoquinolines (e.g., imiquimod).
    - **TLR9:** Detects unmethylated cytosine-phosphate-guanosine (CpG) DNA dinucleotide motifs abundant in prokaryotic genomes (which lack the extensive cytosine methylation typical of mammalian chromatin).
- **TLR Downstream Signaling Transduction Pathways:**
  - *MyD88-Dependent Pathway (Utilized by all TLRs except TLR3):* Engagement recruits myeloid differentiation primary response 88 (MyD88), which complexes with interleukin-1 receptor-associated kinases (IRAK-4, IRAK-1, IRAK-2) and TRAF6. This activates TAK1, leading to phosphorylation and degradation of $I\kappa B$ via the IKK complex ($IKK\alpha$, $IKK\beta$, and NEMO/$IKK\gamma$). Liberated NF-$\kappa$B translocates to the nucleus to induce transcription of pro-inflammatory cytokines ($TNF-\alpha$, $IL-1\beta$, $IL-6$, $IL-12$).
  - *TRIF-Dependent Pathway (Utilized by TLR3 and TLR4):* Recruitment of TIR-domain-containing adapter-inducing interferon-$\beta$ (TRIF) activates TRAF3, TBK1, and $IKK\epsilon$. This phosphorylates interferon regulatory factor 3 (IRF3), which homodimerizes, enters the nucleus, and drives expression of Type I interferons ($IFN-\alpha$, $IFN-\beta$) to induce an antiviral state.
- **RIG-I-Like Receptors (RLRs):** Cytosolic RNA helicases including RIG-I (retinoic acid-inducible gene I), MDA5 (melanoma differentiation-associated protein 5), and LGP2. RIG-I detects short, uncapped, 5'-triphosphate ($5'\text{-PPP}$) or 5'-diphosphate blunt-ended viral dsRNA lacking 2'-O-methylation. MDA5 detects long dsRNA webs. Upon binding, their caspase activation and recruitment domains (CARDs) interact with mitochondrial antiviral-signaling protein (MAVS), triggering downstream TBK1/$IKK\epsilon$ cascades that activate IRF3, IRF7, and NF-$\kappa$B to induce Type I interferons.
- **C-Type Lectin Receptors (CLRs):** Plasma membrane receptors (e.g., Dectin-1, Dectin-2, Mincle) that bind specific carbohydrate moieties on fungal and bacterial walls via calcium-dependent carbohydrate-recognition domains. Dectin-1 recognizes $\beta(1\rightarrow 3)$ glucans, whereas Dectin-2 and Mincle bind high-mannose structures. Downstream signaling through immunoreceptor tyrosine-based activation motifs (ITAMs) and the Syk-CARD9 pathway triggers phagocytosis and inflammatory cytokine production.
- **Exogenous Lectins and Enterocyte Toxicity:** Dietary plant lectins, such as phytohaemagglutinin (PHA from raw/undercooked kidney beans), resist gastric proteolysis and bind directly to branching N-glycans (complexed via GnT-V and GnT-III transferases) on enterocyte microvillar glycocalyces. This cross-linking disrupts enterocyte brush-border architecture, induces microvillar blunting, accelerates epithelial cell sloughing, and provokes immediate acute enteritis characterized by nausea, severe vomiting, abdominal cramping, and secretory diarrhea.

- **Nucleotide-Binding Oligomerization Domain-Like Receptors (NLRs):** Cytosolic sensors containing a central NACHT domain, C-terminal LRRs, and N-terminal effector domains. NOD1 detects meso-diaminopimelic acid (iE-DAP) found mostly in Gram-negative bacteria; NOD2 detects muramyl dipeptide (MDP) common to all peptidoglycan.
- **Dedicated DAMP Receptors:**
  - **P2X7 Receptor:** ATP-gated cation channel on macrophages and monocytes that opens upon binding micromolar concentrations of extracellular ATP (normally confined intracellularly at $\approx 3 - 10\,\text{mM}$), promoting potassium ($K^+$) efflux.
  - **RAGE (Receptor for Advanced Glycation Endproducts):** Binds high mobility group box 1 (HMGB1, extruded by necrotic nuclei), S100 calgranulins, and advanced glycation adducts, driving sustained vascular inflammation.

• The NLRP3 Inflammasome Assembly and Pyroptosis:

  • The Two-Signal Model of Activation:

  • Signal 1 (Priming): Extracellular PAMPs or DAMPs engage membrane TLRs or cytokine receptors ($IL-1R$, TNFR), activating NF-$\kappa$B. This drives transcriptional upregulation of resting, enzymatically inactive pro-IL-$1\beta$, pro-IL-18, and NLRP3 sensor proteins.

  • Signal 2 (Triggering & Assembly): Diverse downstream cellular stressors trigger structural assembly of the inflammasome complex without requiring direct physical binding to the sensor. Triggers include intracellular potassium ($K^+$) efflux, mitochondrial reactive oxygen species (ROS), lysosomal destabilization caused by phagocytosed crystals (monosodium urate, silica, asbestos, cholesterol), or pore-forming bacterial toxins (e.g., nigericin).

  • Inflammasome Architecture: The active NLRP3 sensor undergoes oligomerization via its NACHT domain, using its pyrin domain (PYD) to recruit the bipartite adaptor ASC (Apoptosis-associated speck-like protein containing a CARD). ASC's CARD domain then binds the CARD of pro-caspase-1, creating a macromolecular complex.

  • Enzymatic Cleavage & Cytokine Release: Pro-caspase-1 undergoes autocatalytic cleavage to yield active caspase-1. Active caspase-1 enzymatically cleaves inactive pro-IL-$1\beta$ ($31\,\text{kDa}$) and pro-IL-18 ($24\,\text{kDa}$) into mature, bioactive cytokines ($17\,\text{kDa}$ and $18\,\text{kDa}$, respectively).

  • Pyroptotic Pore Formation: Active caspase-1 simultaneously cleaves the cytosolic protein gasdermin-D (GSDMD), severing its autoinhibitory C-terminal domain to liberate the pore-forming N-terminal fragment (N-GSDMD). N-GSDMD oligomerizes within the inner leaflet of the plasma membrane, forming large, non-selective transmembrane conduits ($10 - 14\,\text{nm}$ inner diameter). This disrupts osmotic gradients, causing rapid cell swelling, plasma membrane rupture, and release of intracellular contents alongside active cytokines—a form of pro-inflammatory programmed cell death termed pyroptosis.

  • Pathology of Gout: Precipitation of monosodium urate (MSU) crystals in peripheral joints with low temperatures (most notably the first metatarsophalangeal joint, termed podagra) drives intense localized inflammation. Synovial resident macrophages ingest needle-shaped MSU crystals, causing phagolysosomal destabilization and cathepsin B release into the cytosol. This triggers NLRP3 assembly and caspase-1 activation, driving massive IL-$1\beta$ secretion that recruits waves of neutrophils into the joint fluid.

• Atherosclerosis and Silicosis Connections:

  • Atherosclerosis: Phagocytosis of crystalline cholesterol by vascular subendothelial macrophages triggers NLRP3 activation, sustaining chronic, low-grade vascular inflammation that promotes atheromatous plaque destabilization.

  • Silicosis: Inhaled silica particulates or asbestos fibers cannot be enzymatically digested by alveolar macrophages, causing chronic lysosomal rupture, persistent NLRP3 inflammasome firing, and relentless secretion of IL-$1\beta$ and transforming growth factors that drive pulmonary fibrosis.

  • Trained Immunity (Innate Immune Memory):

• Innate myeloid cells (monocytes, macrophages) and their bone marrow progenitors can undergo sustained, long-term functional reprogramming following an initial primary challenge.

• Distinct from adaptive memory: does not involve somatic V(D)J gene recombination or clonally distributed antigen-specific receptors.

• Mechanism: Exposure to stimuli like Bacillus Calmette–Guérin (BCG) vaccine, fungal $\beta$-glucans, or oxidized LDL (oxLDL) induces stable epigenetic modifications (e.g., histone methylation such as $H3K4me3$ and acetylation such as $H3K27ac$) and metabolic rewiring (a persistent shift from oxidative phosphorylation to aerobic glycolysis via the Warburg effect).

• Functional Consequence: Upon secondary challenge with unrelated, heterologous pathogens or endogenous stressors months later, trained myeloid cells mount a faster, more robust pro-inflammatory cytokine response ($TNF-\alpha$, $IL-1\beta$, $IL-6$). While protective against reinfection, trained immunity can also drive chronic vascular pathology, as seen when hyperglycemia or hypercholesterolemia reprograms bone marrow myeloid progenitors to accelerate atherosclerosis.

The Complement System

• General Architecture: A heat-labile proteolytic cascade of over 30 soluble plasma proteins and membrane-bound receptors, primarily synthesized by hepatocytes. Circulate as inactive zymogens designated C1 through C9.

• Zymogen Nomenclature Convention: Proteolytic cleavage splits complement zymogens into a smaller "a" fragment (which acts as a soluble, diffusive inflammatory mediator or anaphylatoxin) and a larger "b" fragment (which binds covalently to the microbial surface to assemble downstream convertases). Exception: In historical texts, the larger cleavage product of C2 is sometimes designated C2a and the smaller fragment C2b; however, functionally, the active enzymatic fragment that binds C4b to form C3 convertase is designated C2a (or C2b in modern consensus nomenclature).

• The Three Activation Pathways:

  • 1. The Classical Pathway:

  • Initiation: Triggered when the hexameric C1 complex ($C1q\cdot C1r_2\cdot C1s_2$) binds directly to the Fc regions of antigen-bound antibodies. Binding requires a single pentameric IgM or at least two closely spaced IgG molecules (affinity hierarchy: $\text{IgG3} > \text{IgG1} > \text{IgG2}$; IgG4 cannot activate complement).

  • Enzymatic Assembly: Binding activates C1r, which cleaves and activates the serine protease C1s. Activated C1s cleaves C4 into C4a and C4b, and cleaves C2 into C2b and C2a. C4b covalently attaches to the microbial surface via an exposed reactive internal thioester bond, binding C2a in a $\text{Ca}^{2+}/\text{Mg}^{2+}$-dependent manner to assemble the classical C3 convertase: C4b2a (also designated C4b2b).

  • 2. The Lectin Pathway:

  • Initiation: Antibody-independent. Initiated when soluble circulating pattern-recognition molecules—mannose-binding lectin (MBL) or ficolins—bind repeating arrays of mannose, fucose, or N-acetylglucosamine on microbial envelopes.

  • Enzymatic Assembly: MBL-associated serine proteases (MASP-1, MASP-2) become activated. MASP-2 cleaves C4 and C2, assembling the identical C3 convertase: C4b2a.

  • 3. The Alternative Pathway:

  • Initiation: Constant, low-level spontaneous hydrolysis of the internal thioester bond within circulating native C3, known as "tick-over":       $C3 + H_2O \rightarrow C3(H_2O)$

  • Assembly: $C3(H_2O)$ binds plasma Factor B. Factor D cleaves bound Factor B into Ba and Bb. The resulting fluid-phase complex, $C3(H_2O)Bb$, cleaves intact C3 into C3a and C3b. Liberated C3b forms a covalent ester or amide bond with adjacent cell-surface hydroxyl or amino groups.

  • Surface-bound C3b binds Factor B, which is cleaved by Factor D to form the membrane-stabilized alternative pathway C3 convertase: C3bBb. The plasma protein properdin (Factor P) binds and stabilizes C3bBb, extending its functional half-life tenfold.

• Amplification Loop, C5 Convertase, and the Membrane Attack Complex (MAC):

  • The Amplification Loop: Every C3 convertase cleaves more than 1,000 C3 molecules per second, flooding the microbial surface with covalently attached C3b molecules that can assemble additional C3bBb complexes.

  • C5 Convertase Assembly: Accumulating C3b molecules bind to existing C3 convertases, shifting their substrate specificity from C3 to C5:

  • Classical/Lectin C5 Convertase: C4b2a3b (or C4b2b3b)

  • Alternative C5 Convertase: C3bBb3b

  • Membrane Attack Complex (MAC; C5b-9) Assembly:

  • C5 convertase cleaves C5 into soluble C5a and bioactive C5b.

  • C5b sequentially binds C6 and C7. The hydrophobic sites exposed on C7 insert into the lipid bilayer of the target membrane.

  • C8 binds the C5b67 complex, inserting its $\gamma$ subunit deep into the membrane to cause minor leakage.

  • C5b678 catalyzes the binding and polymerization of 10 to 16 monomers of C9, forming an open, symmetrical cylindrical transmembrane pore ($\approx 10\,\text{nm}$ internal diameter).

  • This allows unregulated entry of water and ions, disrupting osmotic balance and causing rapid lytic cell destruction, especially in thin-walled Gram-negative bacteria like Neisseria.

• Biological and Physiological Effector Functions:

  • Opsonization: C3b and its breakdown product iC3b coat target surfaces, where they are recognized by complement receptors (CR1/CD35, CR3/CD11b-CD18, CR4/CD11c-CD18) on neutrophils and macrophages, promoting rapid phagocytosis.

  • Chemotaxis: C5a acts as a potent chemoattractant, establishing a steep chemical gradient that directs neutrophils, monocytes, and eosinophils toward inflammatory foci.

  • Anaphylatoxin Activity: C3a and C5a bind G-protein-coupled receptors on tissue mast cells and basophils, triggering immediate degranulation with histamine release, smooth muscle contraction, and increased vascular permeability.

  • Immune Complex Clearance: C3b attached to circulating immune complexes binds erythrocyte CR1 receptors. Red blood cells shuttle these complexes safely to the liver and spleen, where sinusoidal macrophages strip and digest them without damaging vessel walls.

• Complement Deficiencies and Clinical Correlations:

  • Early Component Deficiencies (C1q, C1r, C1s, C2, C4): Impair normal solubilization and clearance of circulating immune complexes, predisposing to systemic lupus erythematosus (SLE), severe autoimmune glomerulonephritis, and recurrent pyogenic infections.

  • C3 Deficiency: Central operational defect causing severe, recurrent, life-threatening pyogenic infections (encapsulated bacteria) and membranoproliferative glomerulonephritis.

  • Late Component Deficiencies (C5, C6, C7, C8, C9): Impair MAC assembly, leaving patients specifically vulnerable to recurrent, invasive infections by Neisseria meningitidis and Neisseria gonorrhoeae.

  • Alternative Pathway Component Deficiencies (Factor D, Properdin): Impair spontaneous amplification loops, increasing susceptibility to encapsulated bacterial infections.

Cytokines and Intercellular Signaling Networks

• Operational Modes of Cytokine Delivery:

  • Autocrine: Cytokine binds receptors on the same cell that secreted it (e.g., IL-2 stimulating the proliferation of the activated T cell that synthesized it).

  • Paracrine: Cytokine diffuses locally to bind receptors on immediately adjacent cells (e.g., dendritic cell IL-12 binding nearby naive CD4 T cells).

  • Endocrine: Cytokines enter the systemic circulation to exert physiological effects at distant anatomical sites (e.g., IL-1, IL-6, and $TNF-\alpha$ acting on the hypothalamic thermoregulatory center to induce fever, or on hepatocytes to induce acute-phase reactant synthesis such as C-reactive protein).

• Major Cytokine Classes and Their Signaling Roles:

  • Interleukins (ILs): Primary molecular messengers mediating communication between leukocytes and non-hematopoietic structural cells.

  • Tumor Necrosis Factors ($TNF-\alpha$, $TNF-\beta$/Lymphotoxin-alpha): Master regulators of acute inflammation, endothelial leukocyte-adhesion molecule expression, vascular permeability, and cachexia; cytotoxic to select tumor cells.

  • Interferons (IFNs):

  • Type I ($IFN-\alpha$, $IFN-\beta$): Secreted by virus-infected cells and plasmacytoid DCs; bind the IFNAR receptor, activate the JAK-STAT pathway, and induce an antiviral state via 2'-5'-oligoadenylate synthetase and protein kinase R (PKR), halting host translation and accelerating viral RNA degradation.

  • Type II ($IFN-\gamma$): Produced by NK cells and Th1 lymphocytes; serves as the principal activator of macrophages, enhances MHC expression, and promotes B-cell isotype switching to opsonizing IgG subclasses.

  • Colony-Stimulating Factors (CSFs): Glycoproteins (e.g., GM-CSF, G-CSF, M-CSF, IL-7) that stimulate the survival, proliferation, and differentiation of bone marrow hematopoietic progenitors to replenish peripheral leukocyte populations.

  • Transforming Growth Factor-Beta ($TGF-\beta$): Serves as an immune brake, inhibiting lymphocyte proliferation, antagonizing macrophage activation, promoting extracellular matrix repair, and directing T-cell polarization toward regulatory T cells (Tregs).

  • Chemokines (e.g., CXCL8 / IL-8): Small ($8 - 12\,\text{kDa}$) basic peptides that establish chemotactic gradients, guiding target cells expressing cognate G-protein-coupled seven-transmembrane receptors (e.g., CXCR1, CXCR2) toward damaged or infected tissues.

Major Histocompatibility Complex: Genetics and Architecture

• Genomic Organization of the Human MHC (HLA) Complex:

  • Located on the short arm of chromosome 6 ($6p21.3$), spanning $\approx 3.6 - 4.0\,\text{megabases}$ of DNA and containing over 220 identified gene loci.

• Subregion Division:

  • HLA Class I Region (Telomeric): Encodes the classical heavy polymorphic chains HLA-A, HLA-B, and HLA-C, alongside non-classical molecules (HLA-E, HLA-F, HLA-G, HLA-H).

  • HLA Class II Region (Centromeric): Encodes the polymorphic $\alpha$ and $\beta$ chains organized into three primary classical loci: HLA-DP ($DPA1$, $DPB1$), HLA-DQ ($DQA1$, $DQB1$), and HLA-DR ($DRA$, $DRB1$, $DRB3$, $DRB4$, $DRB5$), plus non-classical antigen-loading accessories (HLA-DM, HLA-DO).

  • HLA Class III Region (Central Intervening): Does not encode antigen-presenting molecules; contains genes for complement proteins (C2, C4A, C4B, Factor B), pro-inflammatory cytokines ($TNF-\alpha$, lymphotoxin-alpha/$TNF-\beta$, lymphotoxin-beta), and heat shock proteins (Hsp70).

  • Genetic Characteristics:

• Polygeny: The presence of multiple, distinct functional genes encoding the same broad class of molecules within an individual genome (e.g., having separate genes for HLA-A, HLA-B, and HLA-C simultaneously).

• Extreme Polymorphism: The presence of numerous allelic variants for each gene locus across the human population. The international IMGT/HLA database documents thousands of distinct alleles (e.g., $>1898$ distinct alleles for HLA-B, $>1365$ for HLA-A, $>1006$ for HLA-C, and $>891$ for HLA-DRB1).

• Codominant Expression: Alleles from both inherited parental chromosomes are expressed equally on the surface of individual cells. Every nucleated diploid cell expresses up to 6 distinct classical MHC Class I proteins (two copies each of HLA-A, HLA-B, HLA-C). Cells expressing MHC Class II display maternal, paternal, and mixed cis/trans heterodimers.

• Linkage Disequilibrium (LD): The non-random association of alleles at different, closely linked loci across a population, such that certain combinations occur together far more frequently than predicted by individual allele frequencies. The conserved European ancestral haplotype HLA-A01:01 - Cw07:01 - B08:01 - DRB103:01 - DQA105:01 - DQB102:01 (often abbreviated A1-B8-DR3-DQ2) exhibits strong linkage disequilibrium, occurring at a population frequency of $\approx 15\%$ in Caucasian Europeans.

• Cis- versus Trans-Complementation: Class II $\alpha$ and $\beta$ polypeptide chains can assemble from genes located on the same chromosome (cis-association) or from opposite homologous parental chromosomes (trans-association). In celiac disease, the high-risk HLA-DQ2.5 heterodimer ($\alpha 1^*05:01, \beta 1^*02:01$) can be encoded in cis on a single DR3-DQ2 haplotype, or in trans in an individual who inherits the $\text{DQA1}^*05:01$ allele from a DR5-DQ7 parent and the $\text{DQB1}^*02:01$ allele from a DR7-DQ2 parent.

• Standardized HLA Nomenclature: Formalized in 2010 using four colon-separated fields:     $\text{HLA-DRB1}^*09:01:02:01\text{N}$

  • HLA-: Gene family prefix.

  • DRB1: Specific gene locus.

  • *: Separator denoting molecular typing.

  • 09 (Field 1): Allele group (corresponds to historical serological antigen specificity, e.g., DR9).

  • 01 (Field 2): Specific, non-synonymous protein-coding sequence alteration.

  • 02 (Field 3): Synonymous (silent) nucleotide mutation within the protein-coding exons.

  • 01 (Field 4): Nucleotide variation located within non-coding regions (introns, 5' or 3' untranslated regions).

  • N (Suffix): Expression modifier denoting a null allele (synthesizes non-functional or unexpressed protein); other suffixes include L (low surface expression), S (secreted form), or Q (questionable expression).

  • Structural Architecture of MHC Molecules:

• MHC Class I Architecture:

  • Polypeptide Structure: Heterodimer consisting of a polymorphic, glycosylated transmembrane $\alpha$ (heavy) chain ($\approx 44 - 47\,\text{kDa}$) non-covalently complexed with an invariant, non-polymorphic light chain, $\beta_2$-microglobulin ($\approx 12\,\text{kDa}$, encoded on chromosome 15).

  • Domains: The $\alpha$ chain folds into three globular domains: $\alpha_1$, $\alpha_2$, and $\alpha_3$. The $\alpha_3$ domain and $\beta_2$-microglobulin fold into classical immunoglobulin-like structures. The $\alpha_3$ domain contains the conserved binding loop that docks the CD8 co-receptor.

  • Peptide-Binding Groove: Composed of eight anti-parallel $\beta$-pleated strands forming a floor flanked by two antiparallel $\alpha$-helices, contributed entirely by the $\alpha_1$ and $\alpha_2$ domains. The ends of the cleft are closed, restricting the length of bound peptides to 8–10 amino acids (most optimally 9-mers). Peptides anchor via conserved non-covalent hydrogen bonding at their free amino and carboxyl termini to conserved tyrosine residues at the pocket edges, combined with sequence-specific interactions at internal hydrophobic anchor pockets (typically at positions P2 and P9/C-terminus).

• MHC Class II Architecture:

  • Polypeptide Structure: Heterodimer consisting of two non-covalently associated, polymorphic transmembrane polypeptide chains: an $\alpha$ chain ($\approx 33 - 35\,\text{kDa}$) and a $\beta$ chain ($\approx 26 - 28\,\text{kDa}$), both anchored in the plasma membrane.

  • Domains: Fold into four extracellular domains: $\alpha_1$, $\alpha_2$, $\beta_1$, and $\beta_2$. The membrane-proximal $\alpha_2$ and $\beta_2$ domains adopt immunoglobulin folds; the $\beta_2$ domain contains the conserved docking site for the CD4 co-receptor.

  • Peptide-Binding Groove: The floor is formed by four $\beta$-strands from $\alpha_1$ and four $\beta$-strands from $\beta_1$, flanked by an $\alpha$-helix from $\alpha_1$ and an $\alpha$-helix from $\beta_1$. The ends of the binding groove are structurally open, accommodating longer peptides of 13–25 amino acids (optimal core of 9 residues with flanking extensions hanging over the ends). Peptides are secured by hydrogen bonds distributed along the peptide backbone, with anchor residues inserting into polymorphic pockets along the cleft (typically at P1, P4, P6, and P9).

Antigen Processing, Presentation, and MHC Restriction

• The Rule of Eight in MHC Restriction:

  • Classical cytotoxic T cells require MHC Class I, mediated by the CD8 co-receptor:     $\text{MHC Class I} \times \text{CD8} = 8$

  • Classical helper T cells require MHC Class II, mediated by the CD4 co-receptor:     $\text{MHC Class II} \times \text{CD4} = 8$

• 1. Endogenous Pathway (MHC Class I Presentation):

  • Target Antigens: Intracellular viral proteins, mutated oncogenic proteins, and intracellular bacterial products synthesized directly within the host cytosol.

  • Proteasomal Cleavage: Ubiquitin ligases tag misfolded or foreign cytosolic proteins with polyubiquitin chains. These tagged proteins enter the standard 26S proteasome (or the immunoproteasome induced by $IFN-\gamma$, which incorporates catalytic subunits LMP2, LMP7, and MECL-1) to be cleaved into oligopeptides of 8–16 amino acids.

  • Translocation via TAP: Oligopeptides are transported across the endoplasmic reticulum (ER) membrane into the lumen via the Transporter associated with Antigen Processing (TAP), an ATP-binding cassette heterodimer composed of TAP1 and TAP2.

  • Chaperone Assembly & Loading: Nascent MHC Class I $\alpha$ chains fold in the ER with the aid of the molecular chaperone calnexin. Once $\beta_2$-microglobulin binds, calnexin dissociates, and the incomplete heterodimer joins the Peptide-Loading Complex (PLC), which includes calreticulin, ERp57, and tapasin. Tapasin physically bridges the MHC Class I cleft to TAP, stabilizing the empty groove. ER aminopeptidase associated with antigen processing (ERAP) trims extended peptides down to the optimal 8–10 amino acid length. High-affinity peptide binding stabilizes the MHC Class I-$\beta_2\text{m}$ complex, releasing it from the PLC.

  • Exocytic Export: Fully assembled peptide-MHC I complexes traverse the Golgi apparatus, undergo glycan maturation, and are ferried via exocytic vesicles to the plasma membrane for inspection by naive and effector $CD8^+$ T cells.

• 2. Exogenous Pathway (MHC Class II Presentation):

  • Target Antigens: Extracellular bacteria, fungal spores, soluble toxins, and matrix proteins internalized by professional APCs (dendritic cells, macrophages, B cells) via receptor-mediated endocytosis, pinocytosis, or phagocytosis.

  • Endosomal Processing: Endocytic vesicles acidify progressively ($\text{pH} \approx 6.0 \rightarrow 4.5$) as they fuse with primary and secondary lysosomes. Acid-dependent endosomal proteases (cathepsins B, D, S, and L) cleave internalized proteins into linear fragments of 13–25 amino acids.

  • Biosynthesis & Invariant Chain (Ii): Newly translated MHC Class II $\alpha$ and $\beta$ chains assemble in the ER. To prevent premature loading with endogenous peptides or misfolded proteins present in the ER lumen, a homotrimeric protein known as the invariant chain (Ii / CD74) inserts its Class II-associated invariant chain peptide (CLIP) domain directly into the peptide-binding cleft. The invariant chain also directs the assembled nonameric complex ($3\,\alpha\beta\text{-heterodimers} + 1\,\text{Ii-trimer}$) out of the ER through the trans-Golgi into late endosomal compartments termed MIIC (MHC Class II compartments).

  • CLIP Removal and HLA-DM Catalysis: Within the MIIC, acid-activated cathepsin S and L cleave the invariant chain, leaving only the short CLIP fragment in the groove. The non-classical, invariant chaperone HLA-DM binds the MHC Class II complex, inducing conformational shifts that release CLIP. HLA-DM stabilizes the empty groove and acts as a peptide editor, ensuring that only high-affinity, stable foreign peptide fragments are loaded.

  • Surface Presentation: Once stably loaded, the peptide-MHC Class II complex is transported in exocytic vesicles to the cell surface, where it is presented to antigen-specific $CD4^+$ helper T cells.

• Cross-Presentation:

  • A specialized process operating primarily in dendritic cells (specifically the cDC1 subset) wherein internalized exogenous antigens escape endosomes into the cytosol, where they are cleaved by the proteasome, transported via TAP into the ER, and loaded onto MHC Class I molecules.

  • Essential for generating primary cytotoxic $CD8^+$ T-cell responses against viral infections that do not directly infect dendritic cells, as well as against evolving tumor cells.

• Superantigens:

  • Unconventional, non-processed bacterial or viral toxins (e.g., Staphylococcal enterotoxins, Toxic Shock Syndrome Toxin-1 / TSST-1, Streptococcal pyrogenic exotoxins) that bypass typical intracellular proteolytic processing.

  • Rather than sitting within the peptide-binding cleft, a superantigen binds simultaneously as an intact protein to the outer lateral face of an MHC Class II molecule and the variable region of a T-cell receptor $\beta$ chain ($V\beta$ domain).

  • Bypasses antigen specificity, activating up to $5\% - 20\%$ of all circulating naive and memory T lymphocytes in the body, triggering massive, systemic release of pro-inflammatory cytokines ($TNF-\alpha$, $IL-1\beta$, $IL-2$, $IFN-\gamma$) leading to acute capillary leak, systemic vasodilation, hypotension, disseminated intravascular coagulation, multiple organ failure, and toxic shock.

T-Lymphocyte Development, Selection, and Priming

• Thymic Development and T-Cell Receptor Generation:

• Double-Negative (DN) Stages (Outer Cortex):

  • Immature $CD34^+$ common lymphoid progenitors enter the thymus at the corticomedullary junction via postcapillary venules as Double-Negative (DN) thymocytes lacking CD4, CD8, and CD3 expression. They progress through four distinct phenotypic stages: DN1 ($CD44^+CD25^-$), DN2 ($CD44^+CD25^+$), DN3 ($CD44^-CD25^+$), and DN4 ($CD44^-CD25^-$).

  • During the DN2 to DN3 transition, Recombination Activating Genes (RAG-1 and RAG-2) initiate somatic V(D)J rearrangement of the TCR $\beta$ chain locus on chromosome 7. Splicing joins a D segment to a J segment, followed by a V segment to the DJ complex.

  • $\beta$-Selection: If the newly rearranged $\beta$ chain successfully pairs with an invariant surrogate pre-T$Storage$ chain (pT$Storage$) to form the pre-TCR complex at the cell surface along with invariant CD3 signaling dimers, the thymocyte receives survival signals. This process triggers allelic exclusion (silencing rearrangement on the second chromosome 7) and initiates rapid clonal proliferation, transitioning the cell into the DN4 stage.

• Double-Positive (DP) Stage (Cortex):

  • Proliferating thymocytes cease pT$Storage$ expression and co-express both the CD4 and CD8 coreceptors alongside invariant CD3 complex molecules ($CD3\gamma\epsilon$, $CD3\delta\epsilon$, and $\zeta\zeta$ homodimers), becoming Double-Positive (DP) thymocytes ($CD3^+CD4^+CD8^+$).

  • RAG-1 and RAG-2 re-engage to direct somatic V-J rearrangement of the TCR $\alpha$ chain locus on chromosome 14, assembling a complete, unique $\alpha\beta\text{-TCR}$.

• Thymic Quality Control:

  • Positive Selection (Thymic Cortex): Cortical thymic epithelial cells (cTECs) present self-peptides complexed with self-MHC Class I and Class II molecules to cortical DP thymocytes. Cells whose TCRs bind self-peptide-MHC complexes with low or moderate affinity receive survival signals. Thymocytes whose TCRs cannot bind any self-MHC molecules undergo apoptosis due to lack of survival signals, a process termed death by neglect (accounting for $\approx 90\%$ of thymocytes). Positive selection enforces self-MHC restriction.

  • Negative Selection (Thymic Medulla): Surviving thymocytes migrate into the thymic medulla, where medullary thymic epithelial cells (mTECs) and medullary dendritic cells present self-peptides. The Autoimmune Regulator (AIRE) transcription factor drives ectopic expression of thousands of peripheral tissue-restricted antigens (TRAs; e.g., insulin, thyroglobulin, myelin basic protein) within mTECs. Thymocytes whose TCRs bind self-peptide-MHC complexes with high affinity undergo apoptotic clonal deletion. Mutations in AIRE disrupt central negative selection, allowing autoreactive T-cell clones to escape into the periphery and cause Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED / APS-1).

• Lineage Commitment (Single-Positive / SP Stage):

  • If a DP thymocyte’s TCR is positively selected on an MHC Class I molecule, it downregulates CD4, matures into a Single-Positive $CD8^+$ cytotoxic T cell, and exits the thymus.

  • If positively selected on an MHC Class II molecule, it downregulates CD8, matures into a Single-Positive $CD4^+$ helper T cell, and enters the systemic circulation.

  • The Three-Signal Model of T-Cell Priming:

• Signal 1 (Antigen Recognition): The TCR binds to its cognate peptide presented within an MHC Class I or Class II molecule on a professional APC. The co-receptor (CD4 or CD8) docks onto conserved non-polymorphic MHC domains ($\beta_2$ or $\alpha_3$, respectively), recruiting the Src-family protein tyrosine kinase Lck to the cytoplasmic tail. Lck phosphorylates immunoreceptor tyrosine-based activation motifs (ITAMs) located within the invariant CD3 complex and $\zeta$ chains, creating high-affinity docking sites for the tandem SH2 domains of ZAP-70 (zeta-chain-associated protein kinase of $70\,\text{kDa}$). Lck phosphorylates and activates ZAP-70, which then phosphorylates the key scaffold adapters LAT (linker for activation of T cells) and SLP-76, assembling a multiprotein signalosome.

• Signal 2 (Co-stimulation): Binding of CD28 constitutively expressed on naive T cells to B7-1 (CD80) or B7-2 (CD86) costimulatory ligands upregulated on mature activated APCs. This co-stimulatory signal stabilizes cytokine mRNA, boosts glucose metabolism, promotes anti-apoptotic protein synthesis (Bcl-xL), and augments intracellular signaling.

  • The First Law of Lymphotics: If a naive T cell receives Signal 1 (TCR ligation) in the absence of Signal 2 (B7 costimulation), the cell enters an irreversible state of metabolic exhaustion and functional unresponsiveness known as clonal anergy, or undergoes activation-induced cell death. This serves as an essential fail-safe for peripheral tolerance against harmless self-antigens.

• Signal 3 (Differentiation Cytokines): Soluble cytokines present within the local microenvironment during initial TCR engagement direct the transcriptional program and lineage commitment of the activated T cell.

• Downstream Transcriptional Cascade & Clonal Expansion:

  • The assembled signalosome activates phospholipase C-gamma-1 ($PLC\gamma 1$), which cleaves membrane phosphatidylinositol 4,5-bisphosphate ($\text{PIP}_2$) into inositol 1,4,5-trisphosphate ($\text{IP}_3$) and diacylglycerol (DAG).

  • $\text{IP}_3$ triggers calcium release from the endoplasmic reticulum, activating the serine/threonine phosphatase calcineurin. Calcineurin dephosphorylates cytoplasmic NFAT (Nuclear Factor of Activated T cells), exposing a nuclear localization sequence that allows NFAT to enter the nucleus.

  • DAG activates protein kinase C-theta ($PKC\theta$), leading to degradation of $I\kappa B$ and nuclear translocation of NF-$\kappa$B.

  • In parallel, the Ras-MAP kinase cascade activates the AP-1 transcription factor heterodimer (c-Fos/c-Jun).

  • NFAT, NF-$\kappa$B, and AP-1 cooperatively bind the promoter of the interleukin-2 (IL-2) gene, driving robust IL-2 transcription. Concurrently, activated T cells express the high-affinity $\alpha$ chain of the IL-2 receptor (CD25), which associates with pre-existing $\beta$ (CD122) and $\gamma$ (CD132) chains to form the trimeric high-affinity IL-2 receptor ($K_d \approx 10^{-11}\,\text{M}$). Autocrine and paracrine IL-2 binding drives massive clonal expansion of antigen-specific effector T cells.

Helper T-Cell Subsets and Cytotoxic Execution

• CD4+ Helper T-Cell Polarizations:

• Th1 Subset:

  • Inducing Cytokines: Interleukin-12 (IL-12) secreted by dendritic cells and macrophages, along with Interferon-gamma ($IFN-\gamma$) from NK cells.

  • Master Transcription Factors: T-bet and STAT4 (also STAT1).

  • Signature Secreted Cytokines: $IFN-\gamma$, IL-2, and Lymphotoxin-alpha (LT-$\alpha$ / $TNF-\beta$).

  • Primary Effector Targets & Pathology: Directs cell-mediated immunity against intracellular pathogens (e.g., Mycobacterium tuberculosis, Listeria monocytogenes, Leishmania). $IFN-\gamma$ hyper-activates macrophages by upregulating iNOS, promoting phagolysosomal maturation, and inducing B-cell switching to opsonizing and complement-fixing IgG subclasses. Overactivation drives chronic inflammatory diseases, organ-specific autoimmunity (e.g., Type 1 diabetes, multiple sclerosis), and delayed-type hypersensitivity.

• Th2 Subset:

  • Inducing Cytokines: Interleukin-4 (IL-4).

  • Master Transcription Factors: GATA-3 and STAT6.

  • Signature Secreted Cytokines: IL-4, IL-5, IL-13, and IL-10.

  • Primary Effector Targets & Pathology: Defends against large extracellular parasitic helminths and ectoparasites. IL-4 drives B-cell immunoglobulin class switching to IgE; IL-5 stimulates eosinophil differentiation, activation, and survival; IL-13 stimulates goblet cell mucus production and intestinal smooth muscle hypermotility. Aberrant Th2 responses drive atopic allergic disorders (allergic rhinitis, asthma, atopic dermatitis, systemic anaphylaxis).

• Th17 Subset:

  • Inducing Cytokines: Transforming Growth Factor-beta ($TGF-\beta$), Interleukin-6 (IL-6), Interleukin-1 (IL-1), with maintenance supported by Interleukin-23 (IL-23).

  • Master Transcription Factors: ROR-gamma-t ($ROR\gamma t$) and STAT3.

  • Signature Secreted Cytokines: IL-17A, IL-17F, IL-21, and IL-22.

  • Primary Effector Targets & Pathology: Clearance of extracellular bacterial pathogens (e.g., Klebsiella pneumoniae) and fungal infections (e.g., Candida albicans); maintains mucosal barrier integrity. IL-17 induces stromal and epithelial expression of G-CSF and CXCL8, recruiting waves of neutrophils into infected tissues. Unchecked Th17 activation drives chronic inflammatory and autoimmune pathologies, including plaque psoriasis, ankylosing spondylitis, and rheumatoid arthritis.

• Follicular Helper T (Tfh) Cells:

  • Inducing Cytokines: IL-6, IL-21, and IL-27.

  • Master Transcription Factors: Bcl-6 and c-Maf.

  • Signature Secreted Cytokines: IL-21 and $IFN-\gamma$.

  • Primary Function: Reside in B-cell follicles of secondary lymphoid organs; express CXCR5, PD-1, and CD40L. Provide critical contact-dependent and cytokine signals to proliferating B cells within germinal centers, driving somatic hypermutation, affinity maturation, and differentiation into long-lived memory B cells and plasma cells.

• Regulatory T (Treg) Cells:

  • Inducing Cytokines: Transforming Growth Factor-beta ($TGF-\beta$) and Interleukin-2 (IL-2).

  • Master Transcription Factors: FoxP3 (Forkhead box P3) and STAT5.

  • Signature Secreted Cytokines: $TGF-\beta$, IL-10, and IL-35.

  • Primary Function: Suppress autoreactive lymphocytes and restrain collateral tissue damage during normal immune responses. Maintain peripheral tolerance via several distinct mechanisms:

    • CTLA-4 Trans-Endocytosis: High constitutive expression of CTLA-4 (CD152) binds CD80 and CD86 on APCs with greater affinity than CD28, physically stripping these costimulatory ligands from the APC surface via trans-endocytosis and preventing naive T cells from receiving Signal 2.

    • Metabolic Disruption: Abundant expression of high-affinity CD25 ($\text{IL-2R}\alpha$) allows Tregs to consume local IL-2, starving effector T cells of survival signals.

    • Immunosuppressive Metabolites: Surface ectoenzymes CD39 and CD73 convert extracellular ATP into immunosuppressive adenosine, which inhibits surrounding effector lymphocytes.

  • CD8+ Cytotoxic T Lymphocyte (CTL) Effector Mechanisms:

• The Immunological Synapse (SMAC Architecture):

  • CTL engagement with an infected or malignant target cell forms a specialized Supramolecular Activation Cluster (SMAC).

  • cSMAC (Central Zone): Contains the TCR-CD3 complexes clustered around peptide-loaded MHC Class I molecules, alongside signaling kinases (Lck, Fyn, ZAP-70).

  • pSMAC (Peripheral Ring): Rich in adhesion molecules, notably LFA-1 (lymphocyte function-associated antigen 1) bound to target-cell ICAM-1 (intercellular adhesion molecule 1). This forms a tight gasket that seals the intercellular cleft, preventing diffusion of cytotoxic molecules into surrounding healthy tissue.

• Lethal Hit via Perforin-Granzyme Exocytosis:

  • TCR signaling polarizes the CTL's microtubule-organizing center (MTOC) and Golgi apparatus directly toward the contact zone, moving lytic granules toward the cSMAC.

  • Granule membranes fuse with the CTL plasma membrane, releasing their contents into the sealed synaptic space.

  • Perforin: Monomers polymerize in the presence of $\text{Ca}^{2+}$, inserting into the target cell membrane to form functional pores ($\approx 13 - 20\,\text{nm}$ diameter).

  • Granzymes: Serine proteases (predominantly Granzyme A and Granzyme B) enter the target cell cytoplasm through perforin pores. Granzyme B cleaves and activates pro-caspase-3 and pro-caspase-7, and cleaves the BH3-only protein Bid into truncated Bid (tBid). tBid translocates to the outer mitochondrial membrane, inducing Bax/Bak oligomerization, releasing cytochrome c into the cytoplasm, assembling the apoptosome, and triggering target cell apoptosis.

• Fas/FasL Apoptotic Induction:

  • Activated CTLs express surface Fas Ligand (FasL / CD178), which binds the death receptor Fas (CD95) expressed on target cells.

  • Trimerization of Fas recruits the adaptor protein FADD (Fas-Associated Death Domain), which engages pro-caspase-8 via death effector domains to assemble the Death-Inducing Signaling Complex (DISC). Caspase-8 undergoes autocatalytic activation, cleaving downstream executioner caspases-3, -6, and -7 to trigger apoptosis independently of mitochondrial permeabilization.

B-Lymphocyte Development, Somatic Recombination, and Activation

• B-Cell Ontogeny in the Bone Marrow:

  • Pro-B Cell Stage:

  • Committed B-cell progenitors in the bone marrow interact with stromal cells via VLA-4/VCAM-1 adhesion and receive essential growth signals from stromal interleukin-7 (IL-7).

  • RAG-1 and RAG-2 recombinases initiate somatic rearrangement at the immunoglobulin heavy chain locus on chromosome 14. D-to-J rearrangement occurs in Early Pro-B cells, followed by V-to-DJ rearrangement in Late Pro-B cells.

  • Pre-B Cell Stage:

  • Successful in-frame VDJ rearrangement leads to translation of the $\mu$ heavy chain ($\mu\text{HC}$). The $\mu\text{HC}$ pairs with an invariant surrogate light chain (composed of $V_{preB}$ and $\lambda_5$) and the signaling heterodimer $\text{Ig}\alpha/\text{Ig}\beta$ (CD79a/CD79b) to form the pre-B-cell receptor (pre-BCR) at the surface of Large Pre-B cells.

  • Signaling through the pre-BCR confirms successful heavy chain rearrangement, triggers allelic exclusion (halting rearrangement on the second chromosome 14), and drives several rounds of cell division.

  • Small Pre-B cells exit the cell cycle and reactivate RAG-1/RAG-2 to rearrange the light chain loci. The $\kappa$ locus on chromosome 2 rearranges first; if both alleles fail to produce a functional light chain, the $\lambda$ locus on chromosome 22 rearranges.

  • Immature B-Cell Stage and Central Tolerance:

  • Assembly of a functional light chain with the $\mu$ heavy chain yields a complete monomeric IgM molecule, displayed at the surface of the Immature B cell as the mature B-cell receptor (BCR).

  • Negative Selection & Receptor Editing: Immature B cells are screened against multivalent self-antigens in the bone marrow. High-affinity cross-linking of immature BCRs by self-antigens does not cause immediate apoptosis; instead, RAG expression remains active, allowing the cell to continue light chain V-J rearrangement—swapping out the autoreactive light chain for an alternative $\kappa$ or $\lambda$ sequence, a process known as receptor editing. If editing successfully eliminates autoreactivity, the cell survives; persistent self-reactive binding triggers clonal deletion (apoptosis).

  • Mature Naive B-Cell Stage:

  • Immature B cells exit the bone marrow and enter secondary lymphoid organs as mature naive B cells, co-expressing surface IgM and IgD with identical antigen-binding specificities. Dual expression is achieved through alternative RNA splicing of a single primary VDJ-C$Storage$ transcript, rather than DNA recombination.

• B-Cell Activation Cascades:

  • Signal 1 (BCR Cross-Linking & Co-Receptor Complex):

  • Multivalent antigen cross-links adjacent membrane immunoglobulins, driving phosphorylation of ITAM motifs on the cytoplasmic tails of invariant $\text{Ig}\alpha$ (CD79a) and $\text{Ig}\beta$ (CD79b) by Src-family kinases (Lyn, Fyn, Blk).

  • Phosphorylated ITAMs recruit Syk (spleen tyrosine kinase), which phosphorylates downstream adaptor proteins (BLNK/SLP-65), activating BTK (Bruton's tyrosine kinase) and PLC$\gamma 2$. This triggers downstream NF-$\kappa$B, NFAT, and MAP kinase activation.

  • Complement Coreceptor Amplification: The B-cell coreceptor complex—composed of CD19, CD21 (Complement Receptor 2 / CR2), and CD81 (TAPA-1)—binds microbial antigens opsonized with complement fragment C3d. C3d binding to CD21 clusters the coreceptor with the BCR, allowing Lyn to phosphorylate the cytoplasmic tail of CD19. This recruits phosphoinositide 3-kinase (PI3K) and amplifies downstream BCR activation signals by 1,000- to 10,000-fold, lowering the threshold for B-cell activation by encapsulated bacteria.

  • Signal 2 (T-Cell-Dependent Help & CD40/CD40L):

  • Protein antigens internalized by BCR-mediated endocytosis are degraded in endolysosomes and presented on MHC Class II molecules.

  • Antigen-activated B cells migrate to the boundary of the lymphoid follicle and T-cell zone, presenting peptide-MHC Class II complexes to primed follicular helper T (Tfh) cells.

  • Tfh cells engage the complex via their TCR and upregulate CD40 Ligand (CD40L / CD154), which binds CD40 constitutively expressed on the B cell.

  • CD40 signaling activates the non-canonical NF-$\kappa$B pathway, inducing expression of Activation-Induced Cytidine Deaminase (AID), an enzyme essential for both immunoglobulin class switch recombination and somatic hypermutation.

• Germinal Center Reaction:

• Activated B cells enter lymphoid follicles, forming dynamic microstructures called germinal centers.

• Dark Zone (Centroblasts & Somatic Hypermutation): Centroblasts proliferate rapidly and express high levels of AID. AID deaminates cytidine residues to uracil within the DNA of rearranged VDJ exons, creating deliberate U:G mismatches. Error-prone DNA repair (via mismatch repair enzymes MSH2/MSH6 or base excision repair via uracil-DNA glycosylase / UNG) introduces random point mutations across the complementarity-determining regions (CDRs), generating clones with altered antigen affinity.

• Light Zone (Centrocytes & Affinity Maturation): Non-dividing centrocytes migrate into the light zone, where follicular dendritic cells (FDCs) display intact, non-processed native antigens held in immune complexes. Centrocytes compete for these limited antigens; those whose mutated BCRs bind with high affinity internalize the antigen, present it on MHC Class II, and receive survival signals from Tfh cells via CD40L and IL-21. Centrocytes with low-affinity or deleterious mutations receive no survival signals and undergo apoptosis. This process of competitive survival progressively enriches the population for high-affinity clones, a process termed affinity maturation.

• Class Switch Recombination (CSR): AID targets highly repetitive switch (S) regions located upstream of heavy chain constant ($C_H$) genes. Deamination creates double-strand DNA breaks in the donor and acceptor switch regions. Non-homologous end joining (NHEJ) splices the rearranged VDJ exon directly to a downstream constant gene (e.g., $C\gamma$, $C\alpha$, or $C\epsilon$), looping out and permanently deleting the intervening DNA. This irreversible recombination switches the antibody isotype (e.g., from IgM to IgG, IgA, or IgE) without altering its VDJ antigen specificity.

• Terminal Differentiation:

  • Centrocytes that survive affinity maturation and class switching differentiate into either Long-Lived Plasma Cells (which downregulate surface BCRs and MHC Class II, home to the bone marrow, and continuously secrete thousands of high-affinity antibodies per second for years) or Memory B Cells (which recirculate through blood and lymphoid follicles, poised to launch immediate high-affinity IgG/IgA responses upon antigen re-exposure).

Immunoglobulins: Structure, Isotypes, and Functions

• Immunoglobulin Molecular Structure:

  • Symmetrical four-chain heterotetramer composed of two identical heavy (H) chains ($\approx 50 - 75\,\text{kDa}$ each) and two identical light (L) chains ($\approx 25\,\text{kDa}$ each), covalently linked by interchain disulfide bonds.

• Functional Proteolytic Cleavage Fragments:

  • Papain Cleavage: Cleaves the heavy chain above the hinge region, producing three separate fragments: two identical Fab (Fragment antigen-binding) fragments—each containing one complete light chain and the $V_H\text{-}C_H1$ domains of one heavy chain, monovalent for antigen—and one Fc (Fragment crystallizable) fragment composed of the dimerized, glycosylated carboxy-terminal $C_H2\text{-}C_H3$ (and $C_H4$) domains, which mediates effector functions by binding Fc receptors and complement.

  • Pepsin Cleavage: Cleaves below the hinge disulfide bonds, generating a single bivalent $\text{F(ab')}_2$ fragment (capable of cross-linking antigens and forming precipitates) and multiple small digested peptides of the Fc region ($\text{pFc'}$).

• The Variable Domain: Amino-terminal domains ($V_H$ and $V_L$) contain framework regions flanking three hypervariable loops termed Complementarity-Determining Regions (CDR1, CDR2, CDR3). Folded together, the CDRs form the antigen-binding surface, or paratope, which binds the matching epitope on the target antigen.

  • Detailed Characteristics of Immunoglobulin Isotypes:

• IgM:

  • Structure: Secreted as a star-shaped pentamer held together by disulfide bonds linking adjacent Fc tails, coordinated by a single $15\,\text{kDa}$ J (joining) chain; also exists as an unjoined hexamer. Membrane-bound BCR form is a monomer.

  • Valence: 10 functional antigen-binding sites per pentamer (theoretical valence 10; steric hindrance may limit effective binding of large antigens to 5).

  • Abundance & Half-Life: Comprises $\approx 4\% - 10\%$ of adult serum immunoglobulins; serum half-life is $\approx 5\,\text{days}$.

  • Effector Functions: The primary antibody produced during an initial immune response. Due to its multimeric structure, it has high avidity despite lower initial intrinsic affinity. A single bound pentameric IgM can undergo a "staple" conformational change that exposes C1q binding sites on its $C\mu 3$ domains, activating the classical complement cascade with high potency. Does not cross the human placenta.

• IgG:

  • Structure & Subclasses: Monomeric configuration (valence of 2). Subdivided into four subclasses based on heavy chain differences: IgG1 ($\approx 65\%$ of total IgG), IgG2 ($\approx 25\%$), IgG3 ($\approx 7\%$), and IgG4 ($\approx 3\%$). IgG3 has an extended hinge region with multiple disulfide bonds, conferring flexible antigen binding and high complement-activating potency, but shortens its serum half-life to $\approx 7\,\text{days}$ compared to $\approx 21 - 23\,\text{days}$ for IgG1, IgG2, and IgG4.

  • Abundance: The predominant isotype in normal human serum, accounting for $\approx 75\% - 80\%$ of total circulating immunoglobulins ($\approx 800 - 1600\,\text{mg/dL}$).

  • Effector Functions: The workhorse of secondary humoral immunity; neutralizes toxins and viruses, opsonizes microbes for phagocytosis, fixes complement (hierarchy: $\text{IgG3} > \text{IgG1} \gg \text{IgG2}$; IgG4 is inactive), and directs antibody-dependent cell-mediated cytotoxicity (ADCC) by NK cells. IgG is the only immunoglobulin class capable of traversing the syncytiotrophoblast layers of the human placenta via the neonatal Fc receptor (FcRn), providing passive protective immunity to the neonate for the first 6 months of life.

• IgA:

  • Structure: Circulates in serum primarily as a monomer ($\approx 10\% - 15\%$ of serum immunoglobulins; $\approx 100 - 400\,\text{mg/dL}$). In secretions (saliva, tears, colostrum, breast milk, tracheobronchial and gastrointestinal mucus), it exists as a dimer (valence of 4) linked by a J chain and wrapped by a dynamic $70\,\text{kDa}$ polypeptide known as the secretory component.

  • Subclasses: Two subclasses: IgA1 (predominates in serum and upper respiratory tract) and IgA2 (features a truncated, protease-resistant hinge, predominating in the protease-rich lumen of the lower gastrointestinal tract).

  • Transcytosis Mechanism: Dimeric IgA produced by mucosal lamina propria plasma cells binds the polymeric immunoglobulin receptor (pIgR) expressed on the basolateral surface of overlying epithelial cells. The complex is endocytosed, transported across the cell in an endocytic vesicle, and cleaved at the apical membrane, releasing the dimeric IgA attached to the cleaved extracellular portion of pIgR—the secretory component. The secretory component protects the antibody against proteolytic degradation by intraluminal digestive enzymes.

  • Effector Functions: Dominant defense across mucosal surfaces; neutralizes pathogens and toxins by blocking epithelial adherence without triggering damaging inflammatory cascades (does not activate classical complement). Secreted IgA in maternal colostrum and breast milk coats the neonate's gastrointestinal tract, conferring passive mucosal immunity.

• IgE:

  • Structure: Monomeric immunoglobulin containing an extra heavy-chain constant domain ($C\epsilon 4$) instead of an extended hinge region; contains complex carbohydrate chains.

  • Abundance & Half-Life: The least abundant isotype in serum, representing only $\approx 0.004\%$ of total circulating immunoglobulins ($\approx 10 - 400\,\text{ng/mL}$ or international units). Circulating serum half-life is short ($\approx 2 - 3\,\text{days}$); once bound to high-affinity receptors, it persists on tissue cells for weeks to months.

  • Effector Functions: Mediates immunity against parasitic helminths and ectoparasites by binding high-affinity receptors ($Fc\epsilon RI$) on mast cells, basophils, and eosinophils. Subsequent antigen cross-linking triggers immediate release of histamine, proteases, and lipid mediators. Drives Type I hypersensitivity (allergic asthma, atopic eczema, allergic rhinoconjunctivitis, and systemic anaphylaxis).

• IgD:

  • Structure: Monomeric immunoglobulin (valence of 2); accounts for $<0.25\%$ of total serum immunoglobulins; highly susceptible to proteolysis.

  • Function: Expressed alongside IgM on the surface of mature naive B cells, serving as a functional antigen receptor; trace amounts in serum have poorly understood regulatory roles.

Cellular Cytotoxicity: NK Cells and Innate Lymphoid Cells

• Natural Killer (NK) Cells:

  • Large, granular, non-phagocytic innate lymphocytes developing from common lymphoid progenitors; do not express variable, rearranged antigen-specific receptors (lacking CD3, TCR, and surface immunoglobulins); phenotypically identified by expression of CD56 (NCAM) and CD16 ($Fc\gamma RIII$).

  • The Missing Self Hypothesis:

  • Healthy nucleated cells continuously express classical MHC Class I molecules on their surface.

  • NK cells bear diverse transmembrane inhibitory receptors (e.g., Killer Cell Immunoglobulin-Like Receptors / KIRs recognizing HLA-A, -B, -C, and CD94/NKG2A heterodimers recognizing non-classical HLA-E) that possess immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in their cytoplasmic tails.

  • Basal engagement of normal self-MHC Class I by these inhibitory receptors recruits tyrosine phosphatases (SHP-1, SHP-2), dephosphorylating downstream activation intermediates and delivering a dominant "do-not-kill" signal.

  • Many viruses (e.g., cytomegalovirus) and transformed tumor cells downregulate MHC Class I to evade detection by $CD8^+$ CTLs. When an NK cell encounters a cell lacking normal MHC Class I, its inhibitory receptors are disengaged ("missing self").

  • The Dual-Signal Balance: NK cell activation is non-binary and depends on the net balance between inhibitory and activating signals. Activating receptors (e.g., NKG2D, NKp30, NKp44, NKp46) recognize stress-induced ligands (e.g., MIC-A, MIC-B, and ULBP proteins) upregulated on infected, DNA-damaged, or transformed cells. If activating signals outweigh inhibitory signals, cytotoxicity is triggered.

  • Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC):

  • NK cells express the low-affinity Fc receptor $Fc\gamma RIII$ (CD16), which binds the clustered Fc domains of IgG1 and IgG3 antibodies coating an infected or malignant cell.

  • CD16 engagement bypasses inhibitory signals, directly triggering exocytosis of perforin and granzymes, inducing target cell apoptosis and stimulating rapid secretion of $IFN-\gamma$.

• Innate Lymphoid Cells (ILCs):

  • Tissue-resident, non-cytotoxic lymphoid sentinels that mirror helper T-cell subsets in transcription factor profiles and cytokine production, but lack somatic V(D)J-rearranged antigen receptors:

  • Group 1 ILCs (ILC1): Express T-bet; respond to IL-12 and IL-18 by secreting $IFN-\gamma$ to direct mucosal defenses against intracellular viruses and bacteria.

  • Group 2 ILCs (ILC2): Express GATA-3; respond to epithelial alarmins (TSLP, IL-25, IL-33) by secreting IL-4, IL-5, IL-9, and IL-13, orchestrating anti-helminth defense and driving allergic inflammation.

  • Group 3 ILCs (ILC3 & LTi cells): Express $ROR\gamma t$; respond to IL-1$\beta$ and IL-23 by producing IL-17 and IL-22, maintaining epithelial barrier integrity and antimicrobial peptide secretion.

Hypersensitivity Mechanisms and Allergic Pathology

• The Classical Coombs and Gell Classification:

• Mechanistic Insights across Hypersensitivity Types:

  • Type I Hypersensitivity Kinetics:

  • Sensitization: Allergens traverse epithelial barriers, are captured by dendritic cells, and are presented to naive T cells, driving Th2 polarization via IL-4. Th2 cells stimulate B cells through CD40-CD40L and IL-4/IL-13 to undergo class switching to IgE. Secreted IgE binds with high affinity ($K_d \approx 10^{-10}\,\text{M}$) to $Fc\epsilon RI$ on the surface of tissue mast cells and circulating basophils.

  • Immediate Phase (Minutes): Re-exposure to multivalent allergen cross-links membrane-bound IgE-$Fc\epsilon RI$ complexes. This activates Lyn and Syk kinases, mobilizing intracellular calcium and causing rapid exocytosis of preformed granule mediators within 5 minutes (histamine, heparin, neutral tryptase). Histamine acts on $H_1$ receptors, causing arteriolar vasodilation, endothelial contraction with capillary leakage, smooth muscle bronchoconstriction, and glandular mucus hypersecretion.

  • Intermediate Lipid Phase (5–30 Minutes): Phospholipase $A_2$ activation cleaves membrane phospholipids to generate arachidonic acid, which is metabolized via the 5-lipoxygenase pathway into cysteinyl leukotrienes ($\text{LTC}_4$, $\text{LTD}_4$, $\text{LTE}_4$; potent bronchoconstrictors and promoters of vascular permeability) and via the cyclooxygenase pathway into prostaglandin $D_2$ ($\text{PGD}_2$).

  • Late Phase Reaction (Hours): Sustained cytokine release ($TNF-\alpha$, IL-4, IL-5, IL-13) recruits circulating eosinophils, neutrophils, and Th2 lymphocytes, driving persistent tissue edema, epithelial desquamation, and chronic inflammation.

• Type II Hypersensitivity and Roitt's Subtype V Classification:

  • Autoantibodies directed against cell surface or structural tissue antigens cause destruction through three mechanisms: opsonization promoting phagocytosis, classical complement activation generating the MAC, or recruit of NK cells via ADCC.

  • Subtype V (Stimulating/Inhibitory Antibodies): Antibodies alter cell function without directly causing cytotoxicity or inflammation:

    • Stimulating: In Graves' disease, autoantibodies bind the thyroid-stimulating hormone (TSH) receptor, mimicking TSH and triggering continuous adenylyl cyclase activation, causing unregulated thyroid hormone synthesis ($T_3/T_4$) and thyrotoxicosis.

    • Blocking: In Myasthenia gravis, autoantibodies bind and internalize muscle nicotinic acetylcholine receptors (AChR) at the neuromuscular junction, blocking neuromuscular transmission and causing progressive muscle weakness and fatigue.

• Type III Hypersensitivity:

  • Soluble antigens complex with circulating IgG or IgM antibodies. Slight antigen excess favors formation of small, soluble immune complexes that evade phagocytic clearance.

  • Complexes deposit in filter beds under high hydrostatic pressure (e.g., renal glomerular basement membranes, synovial capillaries, dermal venules).

  • Deposited complexes bind C1q, activating the classical complement cascade. C3a and C5a recruit neutrophils, which engage complexed antibodies via $Fc\gamma R$. Because the complexes are anchored to the vascular basement membrane, neutrophils release lysosomal enzymes and ROS extracellularly ("frustrated phagocytosis"), causing necrotizing vasculitis and glomerulonephritis.

• Type IV Hypersensitivity (Delayed-Type):

  • Allergic Contact Dermatitis: Low-molecular-weight reactive chemicals (e.g., nickel ions released from inexpensive metal jewelry, urushiol from poison ivy) act as haptens. They penetrate the stratum corneum and covalently bind native epidermal proteins, creating immunogenic neo-antigenic complexes. Epidermal Langerhans cells take up these haptenated proteins, migrate to regional lymph nodes, and prime naive T cells into sensitized memory clones.

  • Secondary Exposure: Re-encounter triggers memory T cells to infiltrate the dermis, where they secrete $IFN-\gamma$, CXCL8, and CCL2. These cytokines recruit and activate macrophages, inducing intraepidermal spongiosis, vesiculation, erythema, and severe pruritus peaking 48–72 hours after exposure.

• The Allergic March:

  • The characteristic clinical progression of atopic manifestations throughout childhood:     $\text{Atopic Eczema / Food Allergy (Infancy)} \longrightarrow \text{Allergic Asthma (Childhood)} \longrightarrow \text{Allergic Rhinoconjunctivitis (Adolescence)}$

• Hygiene and "Old Friends" Hypotheses:

  • Hygiene Hypothesis: Proposes that declining family sizes, cleaner living conditions, reduced exposure to early-childhood symbiotic microbes, and widespread antibiotic use skew developing immune systems toward pro-allergic Th2 responses, due to reduced Th1-polarizing stimuli (such as bacterial unmethylated CpG DNA).

  • "Old Friends" / Biodiversity Hypothesis: Emphasizes that tolerance depends on early developmental exposure to non-pathogenic, co-evolved environmental microorganisms found in rural environments, rich natural soils (the "asphalt index"), and stable commensal gut and skin microbiota, which stimulate FoxP3+ regulatory T cells and induce suppressive cytokines ($TGF-\beta$, IL-10).

• Targeted Biological and Desensitization Therapies:

  • Omalizumab: Recombinant humanized IgG1 monoclonal antibody that binds specifically to the $C\epsilon 3$ domain of free human IgE near its binding site for $Fc\epsilon RI$. It forms small, biologically inert trimers or hexamers, preventing IgE from attaching to mast cells, basophils, or dendritic cells. By depleting circulating free IgE, omalizumab downregulates surface expression of $Fc\epsilon RI$, attenuating mediator release and preventing asthma exacerbations.

• Dupilumab: Fully human monoclonal antibody directed against the IL-4 receptor alpha (IL-4R$\alpha$) subunit shared by both the IL-4 (Type I) and IL-13 (Type II) heterodimeric receptor complexes. It blocks signaling by both IL-4 and IL-13, suppressing Th2/Type 2 inflammation, reducing tissue eosinophilia, diminishing mucus production, and providing clinical control in chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and atopic dermatitis.

• Allergen-Specific Immunotherapy (SIT): Long-term administration (3–5 years) of escalating doses of purified, standardized allergen extracts delivered via subcutaneous injections (SCIT) or sublingual tablets/drops (SLIT). Mechanistically induces allergen-specific FoxP3+ Treg and IL-10-producing Tr1 cells. These regulatory cells suppress Th2 responses, shift cytokine production toward Th1 ($IFN-\gamma$), and instruct B cells to switch from IgE to IgG4 production. Non-inflammatory IgG4 acts as a blocking antibody, binding incoming allergens before they can cross-link mast cell-bound IgE, blunting clinical reactions.

Diagnostic Methodologies in Cellular and Humoral Immunology

• Flow Cytometry:

• Fluidics Principle: Cells in single-cell suspension are injected into a central core stream surrounded by a faster-moving outer sheath fluid. Hydrodynamic focusing narrows the core stream, aligning cells into a single-file line that passes sequentially through an interrogation point.

• Optics and Light Scatter:

  • Forward Scatter (FSC): Measures laser diffraction along the axis of the laser beam, directly proportional to cell size / cross-sectional diameter.

  • Side Scatter (SSC): Measures wide-angle light refracted and reflected at approximately $90^\circ$, proportional to internal granularity, organelle complexity, and nuclear lobulation.

  • Intrinsic Scatter Separation: Using FSC and SSC alone (without fluorescent antibodies), peripheral leukocytes separate into three distinct clusters: small, agranular lymphocytes ($\text{low FSC}, \text{low SSC}$); medium, moderately complex monocytes ($\text{intermediate FSC}, \text{intermediate SSC}$); and large, highly granular neutrophils/granulocytes ($\text{high FSC}, \text{high SSC}$).

• Fluorescence Detection: Cells are pre-incubated with fluorochrome-conjugated monoclonal antibodies directed against surface markers (e.g., anti-CD3-FITC, anti-CD4-PE, anti-CD8-APC) or intracellular targets (cytokines, transcription factors like FoxP3, or functional enzymes after membrane permeabilization). Dichroic mirrors and bandpass filters direct emitted light of specific wavelengths to high-sensitivity photomultiplier tubes (PMTs), allowing simultaneous multiparametric phenotypic profiling.

  • In Vivo and In Vitro Cell-Mediated Assays:

• Patch Testing (Epicutaneous Testing):

  • Gold standard for diagnosing Type IV contact hypersensitivity.

  • Standardized allergen-hapten preparations (e.g., nickel sulfate, fragrance mixes, neomycin) formulated in petrolatum are loaded into small inert chambers and taped securely to the patient's upper back for 48 hours.

  • The skin is examined at 48 hours and again at 72–96 hours, scored on an international morphological scale: ?+ (doubtful erythema), + (weak positive: non-vesicular erythema, infiltration), ++ (strong positive: erythema, infiltration, discrete papules and vesicles), and +++ (extreme reaction: coalescent bullae, ulceration).

• Tuberculin Skin Test (Mantoux Reaction): Intradermal injection of 0.1 mL of Purified Protein Derivative (PPD; 5 tuberculin units) into the volar forearm. Memory T cells recognize mycobacterial antigens presented by dermal APCs, recruiting macrophages over 48–72 hours. The transverse diameter of palpable induration (not erythema) is measured in millimeters. Cross-reacts with prior BCG vaccination and environmental non-tuberculous mycobacteria.

• Interferon-Gamma Release Assays (IGRAs; e.g., QuantiFERON-TB):

  • Heparinized whole blood is incubated in vitro with specific synthetic peptides representing Mycobacterium tuberculosis antigens (ESAT-6, CFP-10) that are absent from the BCG vaccine strain and most non-tuberculous mycobacteria.

  • Sensitized memory $CD4^+$ and $CD8^+$ T cells secrete $IFN-\gamma$, which is quantified from the supernatant via ELISA.

  • Highly specific; unaffected by prior BCG vaccination.

  • Immunoassay Principles:

• Binding Equilibrium: The non-covalent interaction between an antigen (Ag) and an antibody (Ab) follows the law of mass action:     $[\text{Ag}] + [\text{Ab}] \rightleftharpoons [\text{Ag-Ab}]$     $\text{Dissociation Constant } K_d = \frac{[\text{Ag}][\text{Ab}]}{[\text{Ag-Ab}]}$

  • Low-affinity interaction: $K_d = 10^{-4} - 10^{-6}\,\text{M}$

  • High-affinity interaction: $K_d = 10^{-7} - 10^{-12}\,\text{M}$

  • Extreme affinity (Biotin-Avidin/Streptavidin): $K_d \approx 10^{-15}\,\text{M}$

• Affinity vs. Avidity: Affinity denotes the thermodynamic binding strength between a single antigen-combining site (paratope) and a single epitope. Avidity (functional affinity) denotes the overall accumulated binding strength of a multivalent antibody interacting with multiple identical repeating epitopes on an antigen surface.

• Assay Configurations:

  • Non-Competitive Sandwich Assay: Relies on two distinct antibodies directed against non-overlapping epitopes on the analyte. A capture antibody immobilized on a solid phase binds the antigen; after washing, a labeled detection antibody is added, forming an antibody-antigen-antibody "sandwich". The measured signal is directly proportional to analyte concentration. Requires multivalent/large protein antigens; cannot be used for small haptens (e.g., steroid hormones, therapeutic drugs).

  • Competitive Immunoassay: Unlabeled analyte in the patient sample competes with a fixed concentration of labeled tracer analyte for a limited number of immobilized antibody-binding sites. The measured signal is inversely proportional to the concentration of analyte in the patient sample.

• Label-Free Optical Methods:

  • Turbidimetry: Measures the reduction in intensity of incident light transmitted straight through a suspension of insoluble antigen-antibody complexes along the light path ($180^\circ$).

  • Nephelometry: Measures light scattered at a specific forward angle (commonly $70^\circ$ or $90^\circ$) away from the incident beam by insoluble immune complexes. As turbidity increases, the scattered light flux reaching the detector increases proportionally, offering higher sensitivity than turbidimetry for measuring serum proteins (immunoglobulins, complement factors, acute-phase reactants).

• The Precipitin Curve (Heidelberger-Kendall Curve):

  • Titrating increasing antigen into a fixed antibody concentration yields a characteristic bell-shaped precipitation curve divided into three zones:

    • Zone of Antibody Excess (Prozone): Excess antibody binds individual antigens monovalently, preventing cross-linking into large insoluble lattices; little precipitate forms.

    • Zone of Equivalence: Antigen and antibody concentrations balance, allowing extensive multivalent cross-linking into large, insoluble, light-scattering three-dimensional immune lattices; maximal precipitation.

    • Zone of Antigen Excess (Postzone / High-Dose Hook Effect): Excess antigen saturates all antibody paratopes, dissolving the lattice into small soluble complexes, causing a false low signal.

• Lateral Flow Immunochromatography (e.g., Rapid Urine hCG Test):

  • Sample fluid hydrates a conjugate pad containing mobile, lyophilized monoclonal anti-human chorionic gonadotropin alpha-subunit ($\alpha\text{-hCG}$) antibodies tagged with colored microparticles (colloidal gold or blue latex).

  • If hCG is present, it forms an immune complex with the labeled antibody. Capillary action draws the fluid along a nitrocellulose membrane.

  • At the Test Line, immobilized monoclonal anti-beta-subunit ($\beta\text{-hCG}$) antibodies capture the moving hCG-anti-$\alpha\text{-hCG}$ complex, forming a sandwich that concentrates the colored beads into a visible line.

  • Excess unbound labeled anti-$\alpha\text{-hCG}$ continues migrating to the Control Line, where it is captured by immobilized anti-mouse IgG antibodies, confirming proper fluid flow.

• Analytical vs. Diagnostic Sensitivity and Specificity:

  • Analytical Sensitivity: The lowest physical concentration of an analyte that an assay can reliably distinguish from background noise (detection limit).

  • Analytical Specificity: The ability of an assay to detect only the intended analyte without cross-reacting with structurally similar molecules.

  • Diagnostic Sensitivity: The proportion of individuals with the target disease who test positive:     $\text{Sensitivity} = \frac{\text{True Positives (TP)}}{\text{True Positives (TP)} + \text{False Negatives (FN)}}$

  • Diagnostic Specificity: The proportion of individuals without the disease who test negative:     $\text{Specificity} = \frac{\text{True Negatives (TN)}}{\text{True Negatives (TN)} + \text{False Positives (FP)}}$

  • Positive Predictive Value (PPV): The probability that a patient with a positive test result actually has the disease:     $\text{PPV} = \frac{\text{TP}}{\text{TP} + \text{FP}}$

  • Negative Predictive Value (NPV): The probability that a patient with a negative test result is truly free of the disease:     $\text{NPV} = \frac{\text{TN}}{\text{TN} + \text{FN}}$

  • Prevalence Dependency: While sensitivity and specificity are intrinsic parameters of a test, PPV and NPV vary with disease prevalence in the population. In low-prevalence screening populations, even an assay with high specificity ($95\%$) will yield a low PPV, with false-positive results outnumbering true positives.

• Hybridoma Technology and Monoclonal Antibody (mAb) Engineering:

• Developed in 1975 by Georges Köhler and César Milstein (awarded the 1984 Nobel Prize in Physiology or Medicine).

• Mice are repeatedly immunized with a purified antigen to induce clonal expansion of antibody-secreting plasma cells.

• Splenic lymphocytes are harvested and fused with immortal, hypoxanthine-guanine phosphoribosyltransferase-deficient ($\text{HGPRT}^-$) mouse myeloma cells using polyethylene glycol (PEG) or electroporation.

• Fused cells are cultured in selective HAT medium (containing Hypoxanthine, Aminopterin, and Thymidine):

  • Aminopterin blocks de novo nucleotide synthesis.

  • Unfused myeloma cells ($\text{HGPRT}^-$) cannot utilize the salvage pathway and die.

  • Unfused primary splenocytes survive only briefly in culture ($1 - 2\,\text{weeks}$) and die naturally.

  • Only successfully fused hybridomas survive: they inherit immortality from the myeloma parent and a functional salvage pathway ($\text{HGPRT}^+$) along with antibody-secreting capability from the primary B cell.

• Clones are isolated by limiting dilution, screened for specific antigen binding via ELISA, and expanded to produce monoclonal antibodies of uniform specificity and affinity.

• Recombinant and Cellular Derivatives:

  • Single-Chain Variable Fragments (scFv): Recombinant fusion proteins consisting of the variable heavy ($V_H$) and variable light ($V_L$) domains connected by a flexible peptide linker.

  • Bispecific T-Cell Engagers (BiTEs): Recombinant molecules comprising two single-chain variable fragments: one arm binds a tumor antigen (e.g., CD19), while the second arm binds CD3 on T cells, mechanically cross-linking polyclonal CTLs to tumor targets.

  • Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Autologous T cells collected via leukapheresis are genetically engineered using viral vectors (e.g., retrovirus, lentivirus) to express an artificial receptor combining an extracellular tumor-targeting scFv, a transmembrane anchor, and intracellular signaling domains (CD28 or 4-1BB costimulatory domains linked to the CD3$\zeta$ activation domain).

Transplantation Immunology, Allorecognition, and Tolerance

• Graft Classifications:

  • Autograft: Tissue transferred from one anatomical site to another within the same individual (e.g., split-thickness skin graft, saphenous vein bypass).

  • Isograft (Syngeneic Graft): Tissue transplanted between genetically identical individuals (monozygotic twins or syngeneic inbred animal strains).

  • Allograft: Tissue transplanted between genetically disparate members of the same biological species (the standard clinical organ transplant scenario).

  • Xenograft: Tissue transplanted between members of different biological species (e.g., pig-to-human organ xenotransplantation).

• Allorecognition Pathways:

• Direct Allorecognition:

  • Recipient naive and memory T cells directly engage intact, foreign allogeneic MHC molecules displayed on donor antigen-presenting cells (donor dendritic cells, termed "passenger leukocytes") that migrate out of the graft into host regional lymph nodes.

  • High Frequency: An extraordinarily high proportion of the recipient's baseline T-cell repertoire ($1\% - 10\%$ of all circulating T cells) can directly cross-react with a foreign MHC molecule. This occurs because the allogeneic MHC presents a dense array of foreign shapes that mimic self-MHC-foreign-peptide conformations, compensating for individual low-affinity interactions through sheer numbers of contact points.

  • Responsible for driving acute cellular rejection.

• Indirect Allorecognition:

  • Recipient dendritic cells infiltrate the graft, scavenge shed donor alloantigens (soluble donor MHC proteins), process them via endosomes, and present the resulting donor-derived peptide fragments within self-MHC Class II molecules to host $CD4^+$ helper T cells.

  • Follows classical rules of self-MHC restriction, recruiting T-follicular helper cells to promote B-cell activation, class switching, and synthesis of high-affinity Donor-Specific Antibodies (DSAs).

  • Drives chronic antibody-mediated and cellular rejection.

• Semi-Direct Allorecognition: Host APCs acquire intact, functional donor MHC Class I and II complexes via trogocytosis (cell-cell contact) or through uptake of donor-derived extracellular vesicles, displaying them on their own surface to activate alloreactive T cells.

  • The Three Waves of Allograft Rejection:

• 1. Hyperacute Rejection:

  • Onset: Occurs within minutes to hours following vascular anastomosis.

  • Mechanism: Mediated by pre-existing circulating donor-specific antibodies (DSAs) in the recipient's bloodstream (formed from previous blood transfusions, prior pregnancies, or earlier organ transplants, or pre-existing natural ABO isohemagglutinins).

  • Antibodies immediately bind allogeneic ABO or HLA Class I molecules expressed on donor graft vascular endothelial cells.

  • This triggers the classical complement cascade, generating C3a and C5a, destroying the endothelial lining, exposing subendothelial collagen, activating platelets, and causing widespread thrombosis, vascular occlusion, parenchymal hemorrhage, and graft necrosis.

• 2. Acute Rejection:

  • Onset: Manifests clinically within days to weeks post-transplantation (can recur months later if immunosuppressive therapy is adjusted).

  • Mechanism: Driven primarily by direct allorecognition. Host $CD8^+$ CTLs attack graft parenchymal cells and vascular endothelial cells (endothelialitis/tubulitis), while $CD4^+$ Th1 cells secrete cytokines ($IFN-\gamma$) that activate destructive macrophages. Can also involve de novo Donor-Specific Antibodies (acute antibody-mediated rejection) directed against HLA, causing complement deposition (C4d) in peritubular capillaries.

• 3. Chronic Rejection:

  • Onset: Develops slowly over months to years; the leading cause of late allograft failure.

  • Mechanism: Driven predominantly by indirect allorecognition and low-grade chronic cell-mediated and humoral responses. T-cell cytokines and macrophage growth factors stimulate vascular smooth muscle cells and fibroblasts to proliferate, leading to progressive concentric intimal hyperplasia, arterial luminal occlusion (graft vasculopathy), tissue ischemia, and parenchymal interstitial fibrosis.

  • The Matching Paradox in Renal Transplantation:

• Matching donor and recipient for classical HLA antigens (specifically HLA-A, HLA-B, and HLA-DR) significantly reduces allosensitization and improves long-term graft survival. HLA-DR matching is clinically the most critical for preventing acute and chronic rejection.

• The Paradox: Completely matched (0-mismatch) allografts from unrelated donors can still undergo acute and chronic rejection due to differences in non-MHC-encoded Minor Histocompatibility Antigens (MiHAs)—polymorphic cellular proteins that differ between individuals and are presented as non-self peptides in shared MHC clefts.

• Conversely, modern immunosuppressive protocols allow poorly matched grafts (up to 6 mismatches across A, B, and DR) to achieve $65\% - 70\%$ 5-year functional graft survival, demonstrating the high efficacy of maintenance pharmacotherapy.

  • Immunosuppressive Pharmacology in Transplantation:

• Calcineurin Inhibitors (CNIs):

  • Cyclosporine: Binds to the intracellular immunophilin cyclophilin, forming a complex that binds and inhibits the calcium-activated serine/threonine phosphatase calcineurin.

  • Tacrolimus (FK506): Binds to FK506-binding protein 12 (FKBP-12), similarly inhibiting calcineurin with higher potency than cyclosporine.

  • Consequence: Inhibits calcineurin-mediated dephosphorylation of NFAT, preventing its nuclear translocation and blocking transcription of IL-2 and other essential T-cell survival cytokines.

• Costimulation Blockers (Belatacept, Abatacept): Soluble fusion proteins combining the extracellular binding domain of human CTLA-4 with a modified Fc portion of human IgG1. They bind CD80 and CD86 on APCs with high affinity, preventing CD28 engagement and inducing functional anergy in alloreactive T cells.

• mTOR Inhibitors (Sirolimus / Rapamycin, Everolimus): Bind intracellular FKBP-12, but instead of inhibiting calcineurin, the complex inhibits the mammalian target of rapamycin (mTOR) kinase. This halts downstream cell-cycle progression from $G_1$ to S phase in response to IL-2 signaling.

• Antimetabolites:

  • Azathioprine: Converted to 6-mercaptopurine (6-MP), which acts as a purine analogue, blocking de novo purine synthesis and halting lymphocyte DNA replication.

  • Mycophenolate Mofetil (MMF): Cleaved to mycophenolic acid, a selective, reversible, non-competitive inhibitor of inosine monophosphate dehydrogenase (IMPDH). Because proliferating lymphocytes rely on the de novo purine pathway rather than the salvage pathway, MMF selectively blocks T- and B-cell proliferation.

• Corticosteroids (Prednisone, Prednisolone, Methylprednisolone): Lipophilic drugs that diffuse across plasma membranes, bind cytosolic glucocorticoid receptors (GR), and translocate to the nucleus. They inhibit key pro-inflammatory transcription factors (NF-$\kappa$B and AP-1), downregulate adhesion molecules and inflammatory cytokines ($IL-1$, $IL-2$, $IL-6$, $TNF-\alpha$), and induce apoptosis in immature lymphocytes.

• Monoclonal and Polyclonal Antibodies:

  • Anti-Thymocyte Globulins (ATG): Polyclonal horse or rabbit antibodies raised against human thymocytes that clear circulating lymphocytes via complement-mediated lysis and opsonization.

  • Basiliximab: Chimeric monoclonal antibody that binds CD25 (the IL-2R$\alpha$ chain) with high affinity, competitively blocking IL-2-driven clonal proliferation during the early post-transplant induction period.

  • Graft-versus-Host Disease (GVHD):

• A major clinical complication occurring almost exclusively following allogeneic Hematopoietic Stem Cell Transplantation (HSCT) or bone marrow transplantation, in which immunocompetent donor-derived T cells mount a systemic immune attack against host tissues.

• Billingham’s Three Essential Prerequisites:

  • 1. The graft must contain immunocompetent, mature donor T cells.

  • 2. The recipient must express foreign transplantation antigens (HLA or MiHAs) absent in the donor, appearing as targets for donor lymphocytes.

  • 3. The recipient must be immunocompromised or unable to mount an effective immune response to reject the donor graft cells.

• Acute GVHD (Within the First 100 Days / 3 Months Post-Transplant):

  • Pathophysiology: Conditioning regimens (chemotherapy, total body irradiation) damage host tissues, releasing massive amounts of DAMPs and PAMPs that activate host dendritic cells. Host APCs present alloantigens to mature donor T cells, which activate and polarize into Th1 and CTL effectors, releasing $IFN-\gamma$, $TNF-\alpha$, and IL-2 to recruit host macrophages.

  • Clinical Triad:

    • Skin: Painful or pruritic maculopapular rash typically starting on the neck, palms, and soles, spreading across the entire body (can progress to generalized bullous formation and toxic epidermal necrolysis-like sloughing).

    • Liver: Cholestasis and epithelial destruction in small bile ducts, presenting with elevated alkaline phosphatase (ALP) and conjugated hyperbilirubinemia, progressing to clinical jaundice.

    • Gastrointestinal Tract: Inflammation of mucosal crypts in the distal small intestine and colon, manifesting as severe watery green diarrhea (often exceeding 1–2 liters per day), intestinal bleeding, abdominal cramping, and mucosal ulceration.

• Chronic GVHD (After 100 Days Post-Transplant):

  • Characterized by immune dysregulation, autoantibody production, and extensive tissue fibrosis.

  • Affects the skin (scleroderma-like dermal thickening, lichenoid changes), mouth and eyes (xerostomia, keratoconjunctivitis sicca / dry eye syndrome), and lungs (bronchiolitis obliterans leading to irreversible airway obstruction).

• Management: High-dose systemic intravenous glucocorticoids (e.g., methylprednisolone) form the first-line standard of care, carefully titrated to suppress alloreactive donor clones while minimizing the risk of opportunistic fungal and viral infections.

  • Xenotransplantation Barriers and Genetic Engineering Solutions:

• Pigs (particularly Yucatan miniature swine) represent ideal non-primate donor candidates due to suitable organ dimensions, breeding efficiency, and compatible physiological profiles.

• Major Rejection Barriers:

  • Hyperacute Rejection via Carbohydrate Xenoantigens: Unlike humans, non-primate mammals express functional $\alpha\text{-1,3-galactosyltransferase}$, which decorates endothelial cell surfaces with galactose-$\alpha$-1,3-galactose ($\alpha\text{-Gal}$) carbohydrate residues. Humans produce high levels of circulating natural IgM anti-$\alpha\text{-Gal}$ antibodies (similar to ABO blood group agglutinins). These antibodies bind donor pig endothelium immediately upon perfusion, triggering catastrophic hyperacute complement-mediated thrombosis.

  • Other Xenoantigens: N-glycolylneuraminic acid (Neu5Gc, encoded by CMAH) and the $\text{Sd}^a$ blood group carbohydrate (encoded by B4GALNT2).

  • Complement Incompatibility: Swine cell-surface complement-regulatory proteins (CD46, CD55, CD59) fail to downregulate activated human complement components.

  • Endogenous Retroviruses: Porcine Endogenous Retrovirus (PERV) sequences embedded in the swine genome carry a theoretical risk of cross-species reactivation in immunosuppressed human hosts.

• Multiplex CRISPR-Cas9 Gene Editing Solutions:

  • Targeted Knockouts: Simultaneous inactivation of GGTA1 (eliminating $\alpha\text{-Gal}$), CMAH (eliminating Neu5Gc), and B4GALNT2 (eliminating $\text{Sd}^a$), combined with genome-wide CRISPR inactivation of all integrated PERV loci.

  • Transgenic Knock-Ins of Human Protective Genes: Insertion of human complement regulators (hCD46, hCD55), human coagulation and endothelial-protective regulators (human thrombomodulin / hTHBD, endothelial protein C receptor / hPROCR), and human anti-inflammatory/immune checkpoint molecules (human CD47 to provide a "don't-eat-me" signal to human macrophages, hHMOX1, and hTNFAIP3).

• Ocular Immune Privilege and Anterior Chamber-Associated Immune Deviation (ACAID):

  • The eye maintains specialized mechanisms to protect visual structures from blinding, immune-mediated damage:

  • Physical Barriers: Tightly joined vascular endothelia form the blood-aqueous and blood-retinal barriers; the cornea is completely avascular and lacks conventional lymphatic drainage channels.

  • Immunosuppressive Microenvironment: Aqueous humor contains high concentrations of soluble immunomodulatory molecules, including $TGF-\beta 2$, macrophage migration inhibitory factor (MIF), alpha-melanocyte-stimulating hormone ($\alpha\text{-MSH}$), calcitonin gene-related peptide (CGRP), and thrombospondin-1 (TSP-1).

  • Membrane-Bound Apoptotic Molecules: Ocular parenchymal and endothelial cells express high levels of Fas Ligand (FasL / CD178) and PD-L1, inducing apoptosis in infiltrating Fas-bearing activated T lymphocytes and neutrophils.

  • Complement Regulation: Local cells express membrane-bound complement-regulatory proteins (CD46, CD55, CD59) to suppress spontaneous alternative and classical complement cascades.

  • ACAID Phenomenon: Soluble antigens introduced into the anterior chamber are captured by specialized ocular $F4/80^+$ antigen-presenting cells that migrate via the blood directly to the spleen and thymus. These APCs direct naive lymphocytes to differentiate into antigen-specific regulatory T cells (Tregs), suppressing systemic delayed-type hypersensitivity (DTH) reactions against ocular antigens while leaving systemic humoral antibody responses intact.

Reproductive Immunology and Maternal-Fetal Tolerance

• The Fetal Allograft Challenge: The developing mammalian fetus expresses both maternal and paternal alleles, presenting a foreign semi-allograft that the maternal immune system must tolerate while preserving systemic defense against environmental pathogens.

• Pre-Conceptional Seminal Priming:

  • Insemination introduces seminal plasma containing high concentrations of paternal antigens, transforming growth factor-beta ($TGF-\beta$), and prostaglandin $E_2$ ($PGE_2$) into the female reproductive tract.

  • This exposure stimulates uterine dendritic cells to promote differentiation of paternal-antigen-specific FoxP3+ regulatory T cells (Tregs), establishing immune tolerance toward paternal alloantigens prior to implantation.

  • Olfactory receptor (OR) genes linked to the MHC region on chromosome 6 influence individual odor profiles and are expressed on spermatozoa, potentially contributing to mate selection patterns that favor MHC heterozygosity.

• Trophoblast HLA Expression Profile:

  • Syncytiotrophoblasts: The outer multinucleated placental layer in direct contact with maternal blood; completely lacks classical MHC Class I (HLA-A, HLA-B) and MHC Class II molecules, preventing direct recognition and attack by maternal alloreactive $CD4^+$ and $CD8^+$ T cells.

  • Extravillous Cytotrophoblasts (EVTs): Invasive fetal trophoblasts that anchor the placenta and remodel maternal spiral arteries; express a specialized, non-classical HLA profile: HLA-C, HLA-E, and HLA-G.

  • HLA-G: Expressed as both membrane-bound and soluble isoforms (solHLA-G1 through solHLA-G6). Binds inhibitory receptors LILRB1 (ILT2) on maternal monocytes/macrophages and KIR2DL4 on decidual NK (dNK) cells, blocking cytotoxicity, promoting vascular remodeling, and inducing local maternal Treg differentiation.

  • HLA-E: Presents conserved leader peptides derived from other HLA molecules, binding the CD94/NKG2A inhibitory receptor on maternal decidual NK cells to prevent cell lysis.

• Peripheral and Local Mechanisms of Tolerance:

  • Continuous shedding of fetal and placental debris (approximately $1\,\text{g/day}$ of syncytiotrophoblast microparticles and exosomes carrying HLA-G, FasL, and placenta-specific microRNAs) enters the maternal circulation, driving systemic paternal-antigen-specific Treg expansion.

  • Decidual macrophages express indoleamine 2,3-dioxygenase (IDO), an enzyme that catabolizes the essential amino acid tryptophan into kynurenine metabolites. Local tryptophan depletion starves proliferating maternal T cells, arresting them in the $G_1$ phase and maintaining immunological tolerance throughout gestation.

HLA in Disease Susceptibility, Pharmacogenomics, and Pre-Transplant Testing

• HLA and Autoimmune Disease Associations:

• Autoimmune diseases affect approximately $5\%$ of the global population, with female-to-male ratios shifting across age groups.

• Ankylosing Spondylitis (AS): Displays a very strong genetic association with HLA-B27. Individuals carrying HLA-B27 have an estimated Relative Risk (RR) of $\approx 90$ for developing ankylosing spondylitis compared to non-carriers, and an RR of $\approx 33$ for Reiter's syndrome (reactive arthritis). The pathogenic mechanisms include:

  • 1. Arthritogenic Peptide Hypothesis: HLA-B27 presents a specific microbial peptide that structurally mimics a self-protein found in vertebral cartilage, triggering cross-reactive autoimmune attack.

  • 2. HLA-B27 Heavy Chain Misfolding: Slow folding of HLA-B27 heavy chains causes accumulation in the ER, triggering the unfolded protein response (UPR) and IL-23 secretion, which drives Th17/IL-17 inflammation.

  • 3. Cell-Surface Homodimer Formation: Aberrant formation of disulfide-linked heavy chain homodimers ($\text{B27}_2$) lacking $\beta_2$-microglobulin binds activating killer-cell receptors (KIR3DL2), stimulating survival of pathogenic IL-17-producing cells.

• Type 1 Diabetes Mellitus (T1D):

  • HLA Risk Architecture: Accounts for up to $60\%$ of the total genetic susceptibility. Highest risk is conferred by the heterozygous HLA-DR3/DR4-DQ2/DQ8 genotype:

    • DR3 haplotype: Consists of $DRB1^*03:01 - DQA1^*05:01 - DQB1^*02:01$.

    • DR4 haplotype: Consists of $DRB1^*04:01 - DQA1^*03:01 - DQB1^*03:02$.

    • Structural Basis: The replacement of a conserved, charged aspartic acid residue at position 57 of the $\text{DQ}\beta$ chain (Asp-57) by uncharged residues (alanine, valine, or serine) alters the electrostatics of the P9 binding pocket, favoring presentation of pancreatic islet antigens (insulin B-chain, glutamic acid decarboxylase 65 / GAD65, islet antigen-2 / IA-2, and ZnT8) to self-reactive T cells.

    • Protective Alleles: The HLA-DR2 haplotype (specifically $DRB1^*15:01 - DQA1^*01:02 - DQB1^*06:02$) confers dominant protection against T1D development.

  • Non-HLA Polygenic Architecture:

    • CTLA4 Gene (Chromosome 2q33): Regulates peripheral tolerance by downregulating B7 costimulation. An A/G single-nucleotide polymorphism at position +49 in exon 1 alters the signal peptide (Thr/Ala). The +49 GG genotype is associated with a $\approx 30\%$ reduction in cell-surface CTLA-4 expression, impaired inhibition of T-cell proliferation, and increased risk for T1D ($\text{Relative Risk} \approx 3$ compared to AA homozygotes).

    • Insulin (INS) Gene (Chromosome 11p15.5): Contains a polymorphic variable number of tandem repeats (VNTR) in its 5' promoter region. Class I VNTR alleles (short, 30–44 repeats) drive lower levels of insulin transcription in the medullary epithelial cells of the thymus, impairing negative selection of insulin-reactive thymocytes and increasing T1D risk ($\text{Relative Risk} \approx 14$ for Class I/I homozygotes compared to Class III/III homozygotes, which feature $>110$ repeats that drive high thymic insulin expression and robust central tolerance).

• Celiac Disease (Gluten-Sensitive Enteropathy): Strongly associated with HLA-DQ2.5 ($\text{DQA1}^*05:01 - \text{DQB1}^*02:01$; $>90\%$ of cases) and HLA-DQ8 ($\text{DQA1}^*03:01 - \text{DQB1}^*03:02$). Tissue transglutaminase-2 (tTG) deamidates uncharged glutamine residues within ingested wheat gliadin peptides into negatively charged glutamic acid. Positively charged basic pockets within HLA-DQ2.5 and HLA-DQ8 bind these deamidated gliadin peptides with high affinity, presenting them to CD4 T cells to drive intestinal mucosal destruction.

• Pharmacogenomics and HLA-B57:01: Carriers of the HLA-B57:01 allele who receive the anti-retroviral reverse transcriptase inhibitor abacavir (used in HIV management) can develop an abacavir hypersensitivity syndrome (fever, rash, gastrointestinal distress, respiratory failure). Abacavir binds non-covalently within the F-pocket of the HLA-B*57:01 cleft, altering its shape and chemical properties, causing it to present novel self-peptides that trigger a systemic, polyclonal cytotoxic T-cell response.

  • Pre-Transplantation Histocompatibility Testing:

• 1. ABO Blood Group Typing: Confirms recipient and donor match for ABO blood group carbohydrate antigens expressed on vascular endothelia, preventing hyperacute rejection mediated by natural isohemagglutinins.

• 2. HLA Typing: Identifies the precise HLA-A, -B, -C, -DR, -DQ, and -DP alleles of both recipient and donor.

  • Historical Serological Typing (CDC): Viable donor lymphocytes are dispensed into multi-well plates pre-loaded with known anti-HLA alloantibodies. Complement is added; if specific antibodies bind the cell surface, complement activates, forming the MAC and lysing the cells. Viability dyes (eosin, trypan blue, or fluorescent ethidium bromide) enter permeable, dead cells, which are scored under phase-contrast or fluorescence microscopy on an international scoring scale:

    • Score 1: Negative ($0\% - 10\%$ dead cells)

    • Score 2: Doubtful positive ($11\% - 20\%$ dead cells)

    • Score 4: Weak positive ($21\% - 50\%$ dead cells)

    • Score 6: Positive ($51\% - 80\%$ dead cells)

    • Score 8: Strong positive ($81\% - 100\%$ dead cells)

- *Molecular DNA Typing (Modern Standard):*
  - **PCR-SSP (Sequence-Specific Primers):** Uses carefully designed primer pairs that amplify only if a specific, matching HLA sequence is present. Amplified products are resolved via agarose gel electrophoresis; presence of an expected band indicates the corresponding allele.
  - **PCR-SSO (Sequence-Specific Oligonucleotide Probes):** Target HLA loci are amplified with universal, locus-specific biotinylated primers. Denatured PCR products are hybridized to a panel of sequence-specific oligonucleotide probes conjugated to fluorescent, barcoded microbeads (Luminex platform), analyzed on an imaging flow analyzer.
  - **Sequencing-Based Typing (SBT & NGS):** Direct Sanger capillary or Next-Generation Sequencing across polymorphic exons (exons 2 and 3 for Class I; exon 2 for Class II), resolving allele assignments at high resolution.

• 3. Panel Reactive Antibody (PRA) / Donor-Specific Antibody (DSA) Screening:

  • Samples recipient serum to quantify the breadth and specificity of pre-existing anti-HLA antibodies. Expressed as the percent Panel Reactive Antibodies (%PRA / %cPRA).

  • Historically conducted via CDC using broad panels of donor lymphocytes; now performed using solid-phase Luminex bead assays coated with individual recombinant human HLA single antigens, detecting bound patient IgG via fluorescent secondary antibodies with high sensitivity.

• 4. Crossmatching (Final Compatibility Check):

  • Performed immediately prior to organ implantation to ensure the recipient lacks pre-formed antibodies directly targeted against the specific donor's cells.

  • Complement-Dependent Cytotoxic (CDC) Crossmatch: Recipient serum is incubated with donor T cells (to test for anti-HLA Class I antibodies) and donor B cells (to test for anti-HLA Class I and Class II antibodies) in the presence of rabbit complement. Lysis indicates pre-formed anti-donor antibodies, representing a contraindication to transplantation.

  • Flow Cytometric Crossmatch: Incubates recipient serum with donor lymphocytes, followed by wash steps and staining with fluorescently labeled anti-human IgG and lineage markers (CD3 for T cells, CD19 for B cells). Detects low-titer, non-complement-fixing donor-specific antibodies with greater sensitivity than CDC assays.

  • Virtual Crossmatch: An electronic assessment comparing the recipient’s confirmed Luminex-derived single-antigen antibody profile directly against the donor’s verified high-resolution molecular HLA genotype, predicting compatibility without requiring immediate physical cell mixing.